Compounds for treating t helper 2 cell-mediated disorders

By modulating TIM receptors and enhancing Tregs, the compound effectively treats Th2 cell-mediated disorders like atopic dermatitis and allergic asthma, addressing the limitations of current immune-suppressive treatments.

WO2026236178A1PCT designated stage Publication Date: 2026-11-12LAPIX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026648
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for T helper 2 (Th2) cell-mediated disorders such as atopic dermatitis and allergic asthma rely on immune suppression, leading to increased infections and adverse effects, limiting their sustained use.

Method used

Administering a therapeutically effective amount of a compound with structural formula (I) or its pharmaceutically acceptable salt to modulate T-cell immunoglobulin mucin (TIM) receptors, selectively inhibiting toll-like receptors (TLR3, TLR7, and TLR9, and enhancing regulatory T-cells (Tregs) to restore immune tolerance.

Benefits of technology

This approach maintains high efficacy and tolerability, reducing inflammation and immune response without general immunosuppression, allowing for sustained treatment of Th2 cell-mediated disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026648_12112026_PF_FP_ABST
    Figure US2026026648_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are methods of treating a T helper 2 (Th2) cell-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the following structural formula:, wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 01367-0015-00PCTCOMPOUNDS FOR TREATING T HELPER 2 CELL-MEDIATED DISORDERS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of US Provisional Patent Application No. 63 / 800,697, filed May 6. 2025, the disclosure of which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Atopic Dermatitis (AD) and allergic asthma are chronic inflammatory disorders with a T helper 2 (Th2) cell-driven pathophysiology, mediated by interleukin 4 (IL-4) and interleukin 13 (IL-13) and characterized by elevated immunoglobulin E (IgE) levels and eosinophilic infiltration (Akids, et al., Allergy, 2020, 75(7): 1582-1605; Facheris, et al., Cell & Mol Biology, 2023, 20:448-474). Treatment of AD focuses on 1) management of pruritus and 2) controlling inflammation and attenuating inflammatory symptoms using similar medications often used in the clinical management of autoimmune diseases carrying the same set of concerns and side effects. The treatment objective in AD is to maintain minimum disease activity (i.e., mild symptoms without rapid exacerbations that affect daily activities). In mild AD, this is often managed by topical anti-inflammatory drugs, such as corticosteroids, calcineurin inhibitors, and crisaborole. Systemic corticosteroids, immunomodulators, and biologics are reserved for long-term maintenance therapy in severe AD (Facheris, et al., Cell & Mol Biology, 2023, 20:448-474, Kulthanan, et a, Asian Pae J Allerg\> Immunol, 2021, 39(3): 145-155).

[0003] However, treatment of AD and other Th2-mediated inflammatory diseases and allergies remains a significant clinical issue. Current approaches rely on general immune suppression at the humoral, cellular and / or complement level, rendering patients immunocompromised and susceptible to opportunistic infections. Furthermore, these therapies have long-established and well-known tolerability issues and / or adverse effects that limit their sustained use.

[0004] Accordingly, there is a need for treatments that can avoid the approach of immune suppression / elimination that leads to increased infections, while maintaining high efficacy and tolerability to allow for sustained use by patients.Attorney Docket No. 01367-0015-00PCTSUMMARY

[0005] Restoring immune tolerance through the enhancement of Tregs and controlling pathogenic T cells (i.e., Th1, Th2 and Th17 cells) presents a potential therapeutic strategy for Th 17 and Th2 cell-mediated diseases,

[0006] The following example embodiments are provided

[0007] One embodiment is a method of treating a T helper 2 (Th2) cell-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural formula (I):or a pharmaceutically acceptable salt of the foregoing, wherein values for the variables (e.g., Ring A, L, R1, R2, R', m) are as described herein.

[0008] Yet another embodiment is a compound having structural formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising such compound or pharmaceutically acceptable salt thereof for use as described herein, e.g.. in treating a Th2 cell-mediated disorder.

[0009] Yet another embodiment is a compound having structural formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising such compound or pharmaceutically acceptable salt thereof for use in the manufacture of a medicament, e.g, for treating a Th2 cell-mediated disorder.BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The foregoing will be apparent from the following more particular description of example embodiments.

[0011] FIG. 1 shows the percentage of Tregs (CD4+ / Foxp3+) and Th2 cells(CD4+ / Gata3+) in PBMCs from patients with allergic asthma described in Example 1.

[0012] FIG. 2 shows that incubation with Compound 2 resulted in a dose-dependent increase in Tregs (CD4+ / Foxp3+) and a dose-dependent decrease in Th2 cells in PBMCs isolated from allergic asthma patients (n=6).

[0013] FIGs. 3A-D show the EASI scores correlated with Th2 levels from four AD patients according to the study described in Example 3, wherein Th2 levels are expressed as a percentage of Th2 cells / total CD4+ T cells.Attomey Docket No. 01367-0015-00PCTDETAILED DESCRIPTION

[0014] A description of example embodiments follows.A. Definitions

[0015] Compounds described herein include those described generally, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version. Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in ‘‘Organic Chemistry”, Thomas Sorrell, University Science Books. Sausalito: 1999, and “March’s Advanced Organic Chemistry”. 5thEd., Ed.: Smith, M. B, and March, J., John Wiley & Sons, New York: 2001, the relevant contents of which are incorporated herein by reference.

[0016] Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H, Pergamon Press, Oxford, 1979, which is incorporated by reference herein for its chemical structure names and rules on naming chemical structures. Optionally, a name of a compound may be generated using a chemical naming program (e.g., CHEMDRAW®, version 17.0.0.206, PerkinElmer Informatics, Inc.).

[0017] When introducing elements disclosed herein, the articles “a,” ‘‘an,” ‘‘the,” and ‘‘said” are intended to mean that there are one or more of the elements. Further, the one or more elements may be the same or different.

[0018] “About” means within an acceptable error range for the particular value, as determined by one of ordinary skill in the art. Typically, an acceptable error range for a particular value depends, at least in part, on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of ± 20%, e.g., ± 10%, ± 5% or ± I % of a given value. It is to be understood that the term “about” can precede any particular value specified herein, except for particular values used in the Exemplification.

[0019] “Alkyd” refers to a branched or straight-chain, monovalent, hydrocarbon radical having the specified number of carbon atoms. Thus, “(Ci -Cyjalkyl” refers to a radical having from 1-8 carbon atoms in a branched or linear arrangement. In some aspects, alkyl is (C1-C30)alkyl, e.g., (C5-C30)alkyl, (C1-C25)alkyl, (C5-C25)alkyl, (Ci-Ci5)alkyl, (C1-C10)alkyl, (Ci-Attorney Docket No. 01367-0015-00PCTC6)alkyl, or (Ci-Cs)alkyl. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl. n-pentyl. isopentyl, neopentyl, 2 -methylpentyl, n-hexyl, and the like. In some aspects, alkyl is optionally substituted, e.g., with one or more substituents described herein.

[0020] “ Ary 1 refers to a monocyclic or polycyclic (e.g., bicyclic, tricyclic), aromatic, hydrocarbon ring system having the specified number of ring atoms. Thus. ‘“(C6-Ci5)aryl” refers to a ring system having from 6-15 ring atoms Examples of aryl include phenyl, naphthyl and fluorenyl. In some aspects, and is optionally substituted, e.g., with one or more substituents described herein.

[0021] “Heteroaryl” refers to a monocyclic or polycyclic (e.g., bicyclic, tricyclic), aromatic, hydrocarbon ring system having the specified number of ring atoms, wherein at least one carbon atom in the ring system has been replaced with a heteroatom selected from nitrogen, sulfur and oxygen. Tims, “(Cs-CislheteroaryF’ refers to a heteroaromatic ring system having from 5-15 ring atoms consisting of carbon, nitrogen, sulfur and oxygen. A heteroaryl can contain 1. 2, 3 or 4 (e g, I, 2 or 3) heteroatoms independently selected from nitrogen, sulfur and oxygen. Typically, heteroaryl is (C5-C2o)heteroaryl, e.g., (Cs-Ci5)heteroaryl, (C5-Ci2)heteroaryl, C5 heteroaryl or Ce heteroaryl. Monocyclic heteroaryls include, but are not limited to, furan, oxazole, thiophene, triazole, triazene, thiadiazole, oxadiazole, imidazole, isothiazole. isoxazole, pyrazole, pyridazine, pyridine, pyrazine, pyrimidine, pyrrole, tetrazole and thiazole. Bicyclic heteroaryls include, but are not limited to, indolizine. indole, isoindole, indazole, benzimidazole, benzofuran, benzothiazole, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridine and pteridine. In some aspects, heteroaryl is optionally substituted, e.g., with one or more substituents described herein.

[0022] “‘Alkoxy” refers to an alkyl radical attached through an oxygen linking atom, wherein alkyl is as described herein. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and the like.

[0023] ‘“Halogen” and “halo” are used interchangeably herein and each refers to fluorine, chlorine, bromine, or iodine. In some aspects, halo is fluoro, chloro or bromo. In some aspects, halo is fluoro or chloro In some aspects, halo is fluoro

[0024] “Haloalkyl” includes mono, poly, and perhaloalkyl groups, wherein each halogen is independently selected from fluorine, chlorine, bromine and iodine (e.g., fluorine, chlorine and bromine), and alkyl is as described herein. In one aspect, haloalkyl is perhaloalkyl (e.g..Attorney Docket No. 01367-0015-00PCTperfluoroalkyl). Examples of haloalky 1 include, but are not limited to, trifluoromethyl and pentafluoroethyl.

[0025] “Haloalkoxy” refers to a haloalkyl radical attached through an oxygen linking atom, wherein haloalkyl is as described herein. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy.

[0026] The term “substituted’' refers to replacement of a hydrogen atom with a suitable substituent. Typically, the suitable substituent replaces a hydrogen atom bound to a carbon atom, but a substituent may also replace a hydrogen bound to a heteroatom, such as a nitrogen, oxygen or sulfur atom. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom. It is also preferred that the substituent, and the substitution, result in a stable compound, e.g, which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Suitable substituents for use herein include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For example, suitable substituents can include halogen, hydroxyl, carbonyl (such as carboxyl, alkoxy carbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkyl, alkoxy, alkylthio, acyloxy, phosphoryl, phosphate, phosphonate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, cycloalkyl, heterocyclyl. aralkyl, aryl or heteroaryl. It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Accordingly, substituents can further include an acetamide, for example.

[0027] The permissible substituents can be one or more and the same or different for appropriate organic compounds. Thus, an “optionally substituted” group is, in some aspects, substituted with 0-5 (e.g.. 0-3, 0, 1, 2, 3, 4, 5) substituents independently selected from halo, (Ci-C6)alkoxy, (Ci-Csjhaloalkoxy. (Ci-Cefalkyl or (Ci-C6)haloalkyl, or optionally substituted (C6-Ci5)aryl or (Cs-Cisfheteroaryl. In some aspects, an optionally substituted ary l or heteroaryl is substituted with 0-5 (e.g.. 0-3, 0, 1. 2, 3, 4, 5) substituents independently- selected from halo, (Ci-Cg)alkoxy. (Ci-Cgfhaloalkoxy, (Ci-Cefalkyl or (Ci-Csfhaloalkyl (e.g., halo, (Ci-CTfalkoxy, (Ci-C’5)haloalkoxy, (Ci-Csfalkyl or (Ci-Cslhaloalkyl) In some aspects, an “optionally substituted” aryl or heteroaryl is substituted with 0-5 (e.g., 0-3, 0, 1, 2, 3, 4, 5) substituents independently selected from halo. (C1-C3)alkoxy, (Ci-C3)haloalkoxy, (Ci-C'3)alkyl or (Ci-Csjhaloalkyl. In some aspects, an optionally substituted (e.g., substituted) alkyl is substituted with 0-5 (e.g. 0-3, 1 or 2, 0, 1, 2. 3, 4, 5) substituents independentlyAttorney Docket No. 01367-0015-00PCTselected from halo (e.g., fluoro), (Ci-Cbjalkoxy, (Ci-C6)haloalkoxy (e.g., (Ci-Celtluoroalkoxy), (C6-Cis)aryl or (C5-Ci5)heteroaryl.

[0028] The term '‘optionally substituted”, as used herein or denoted by a variable followed by a subscript numeral that includes the value 0, as in -(RJ0)P(wherein R30and p are as described herein), means that substitution is optional and, therefore, it is possible for the atom or moiety designated as ‘'optionally substituted” to be unsubstituted or substituted. In some aspects, an optionally substituted group is unsubstituted. When an optionally substituted group denoted herein by a variable followed by a subscript numeral that includes the value 0 is unsubstituted, the subscript numeral following the variable is 0. In some aspects, an optionally substituted group is substituted. When an optionally substituted group denoted herein by a variable followed by a subscript numeral that includes the value 0 is substituted, the subscript numeral following the variable is other than 0. Unless otherwise indicated, e.g., as with the terms ‘'substituted” or “optionally substituted,” a group designated herein is unsubstituted.

[0029] As used herein, the term “compound of the disclosure” refers to a compound of any of the structural formulas depicted herein (e.g, a compound of Structural Formula I, II, III, or Table 1), as well as isomers, such as stereoisomers (including diastereoisomers, enantiomers and racemates) and tautomers thereof, isotopically labeled variants thereof (including those with deuterium substitutions), prodrugs (e.g., alkyd ester prodrugs), and inherently' formed moieties (e.g. polymorphs and / or solvates, such as hydrates) thereof. When a moiety’ is present that is capable of forming a salt, then salts are included as well, in particular, pharmaceutically acceptable salts thereof.

[0030] Compounds of the disclosure may have asymmetric centers, chiral axes, and chiral planes (e.g., as described in: E L. Eliel and S. H. Wilen, Stereo-chemistry' of Carbon Compounds, John Wiley & Sons, New' York. 1994, pages 1119-1190). and occur as racemic mixtures, individual isomers (e.g., diastereomers, enantiomers, geometrical isomers (including cis and trans double bond isomers), conformational isomers (including rotamers and atropisomers), tautomers) and intermediate mixtures, with all possible isomers and mixtures thereof being included, unless otherwise indicated.

[0031] When a disclosed compound is depicted by structure without indicating the stereochemistry', and the compound has one or more chiral centers, it is to be understood that the structure encompasses one enantiomer or diastereomer of the compound separated or substantially separated from the corresponding optical isomer(s), a racemic mixture of the compound and mixtures enriched in one enantiomer or diastereomer relative to itsAttorney Docket No. 01367-0015-00PCTcorresponding optical isomer(s). When a disclosed compound is depicted by a structure indicating stereochemistry, and the compound has one or more chiral centers, the stereochemistry indicates absolute configuration of the substituents around the one or more chiral centers. “R” and “S” can also or alternatively be used to indicate the absolute configuration of substituents around one or more chiral carbon atoms. D- and L- can also or alternatively be used to designate stereochemistry.

[0032] “Enantiomers” are pairs of stereoisomers that are non-superimposable mirror images of one another, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center.

[0033] '‘Diastereomers” are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms

[0034] '‘Racemate” or "racemic mixture,” as used herein, refer to a mixture containing equimolar quantities of two enantiomers of a compound. Such mixtures exhibit no optical activity ( / .<?., they do not rotate a plane of polarized light).

[0035] Percent enantiomeric excess (ee) is defined as the absolute difference between the mole fraction of each enantiomer multiplied by 100% and can be represented by theI R — Ifollowing equation: ee —x 100%, where R and S represent the respective fractions of each enantiomer in a mixture, such that R + S = 1. An enantiomer may be present in an ee of at least or about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99% or about 99.9%.

[0036] Percent diastereomenc excess (de) is defined as the absolute difference between the mole fraction of each diastereomer multiplied by 100% and can be represented by the following equation:, )represent the respective fractions of each diastereomer in a mixture, such that D1 + (D2 + D3 + D4...) = 1. A diastereomer may be present in a de of at least or about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99% or about 99.9%.

[0037] Unless otherwise stated, compounds of the disclosure include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a13C- or14C-ennched carbon are within the scope of this invention. In all provided structures, any hydrogen atom can also be independently selected from deuterium (2II), tritium (3H) and / or fluorine (18F). Such compounds are useful, for example, asAttorney Docket No. 01367-0015-00PCTanalytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.

[0038] The phrase ’‘pharmaceutically acceptable” means that the substance or composition the phrase modifies is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio.

[0039] As used herein, the term ‘'pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M, Berge et al., describe pharmaceutically acceptable salts m detail in J. Pharmaceutical Sciences, 1977, 66. 1-19, the relevant teachings of which are incorporated herein by reference in their entirety. Pharmaceutically acceptable salts of the compounds described herein include salts derived from suitable inorganic and organic acids, and suitable inorganic and organic bases.

[0040] Examples of salts derived from suitable acids include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts derived from suitable acids include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cinnamate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutarate, glycolate, hemisulfate, heptanoate, hexanoate, hydroiodide, hydroxybenzoate, 2-hydroxy-ethanesulfonate, hydroxymaleate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 2-phenoxybenz.oate, phenylacetate. 3-phenylpropionate, phosphate, pivalate, propionate, pyruvate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like

[0041] Either the mono-, di- or tri-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form,

[0042] Salts derived from appropriate bases include salts derived from inorganic bases, such as alkali metal, alkaline earth metal, and ammonium bases, and salts derived fromAttorney Docket No. 01367-0015-00PCTaliphatic, alicyclic or aromatic organic amines, such as methylamine, trimethylamine and picoline, or N+((Ci-C4)alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, barium and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hy droxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.

[0043] Compounds described herein can be provided in prodrug form, e.g.. as ester prodrugs. As used herein, the term “prodrug” refers to a compound that can be hydrolyzed, oxidized, metabolized and / or otherwise react under biological conditions (e.g., in vivo) to provide a compound of Structural Formula I, or a salt thereof (e.g., pharmaceutically acceptable salt thereof). Prodrugs may become active upon reaction under biological conditions (eg. and be biologically inactive), or they may have activity in their unreacted forms. A prodrug may undergo reduced metabolism under physiological conditions (e.g., due to the presence of a hydrolyzable group), thereby resulting in improved circulating half-life of the prodrug (e.g., in the blood). Thus, in some aspects, a prodrug includes a hydrolyzable group, as in an ester prodrug, e.g, an alkyl ester prodrug. Prodrugs can typically be prepared using well-known methods, such as those described by Burger’s Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5thed).

[0044] As used herein, the term “hydrolyzable group" refers to a moiety that, when present in a prodrug. yields a carboxylic acid or salt thereof upon hydrolysis. Hydrolysis can occur, for example, spontaneously under acidic or basic conditions in a physiological environment (e.g, blood, metabolically active tissues such as. for example, liver, kidney, lung, brain), or can be catalyzed by an enzyme(s), (e.g, esterase, peptidases, hydrolases, oxidases, dehydrogenases, lyases or ligases). A hydrolyzable group can confer upon a prodrug advantageous properties in vivo, such as improved water solubility, improved circulating half-life m the blood, improved uptake, improved duration of action, or improved onset of action.

[0045] Examples of hydrolyzable groups include (Ci-Cto)alkyl. (C2-Cio)alkenyl, (C2-Cio)alkynyl, (Ci-Cio)alkoxy(Ci-Cio)alkyl or (Ci-Cio)alkoxy(Ci-Cio)alkoxy(Ci-Cio)alkyl, each optionally substituted with one or more independently selected halo (e.g., fluoro). For example, a hydrolyzable group may be (Ci-Cio)alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl or heptyl, allyl, ethoxymethyl, methoxyethyl, methoxyethoxymethyl or methoxyethoxyethyl. It will be appreciated that when a compound of Structural Formula I is provided in ester prodrug form, the hydrogen ofAttorney Docket No. 01367-0015-00PCTthe carboxylic acid of the compound of Structural Formula I is replaced with a hydrolyzable group, such a hydrolyzable group described herein (e.g, a (Ci-Cio)alkyl optionally substituted with one or more independently selected halo (e.g, fluoro)).

[0046] Compounds described herein can also exist as “solvates” or “hydrates.” A “hydrate” is a compound that exists in a composition with one or more water molecules. A hy drate can include water in stoichiometric quantities, such as a monohy drate or a dihydrate, or can include water in random amounts. A “solvate” is similar to a hydrate, except that a solvent other than water, such as methanol, ethanol, dimethylformamide, diethyl ether, or the like replaces water. Mixtures of such solvates or hydrates can also be prepared. Tire source of such solvate or hydrate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent,

[0047] “Pharmaceutically acceptable carrier” refers to a non-toxic carrier or excipient that does not destroy the pharmacological activity of the agent with which it is formulated and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the agent. Pharmaceutically acceptable carriers that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hy drogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes. polyethylene-poly oxypropylene-block polymers, polyethylene glycol and wool fat.

[0048] “Antigen.” as used herein, refers to any substance that can be recognized by the immune system. “Antigen” broadly encompasses proteins, such as enzymes, peptides, such as polypeptides, carbohydrates, such as polysaccharides, haptens, nucleic acids and grafts. An antigen can be a self-antigen, an antigen produced, under normal conditions or as part of a disorder, by the body, or a foreign antigen, a non-self-antigen. Examples of foreign antigens include antigenic therapies (e.g,. therapeutic proteins, gene therapies, cellular therapies), allergens, and alloantigens.

[0049] “Treating,” as used herein, refers to taking steps to deliver a therapy to a subject, such as a mammal (such as a human), in need thereof (e.g., as by administering to a mammal (such as a human) one or more therapeutic agents, such as a compound disclosed herein, or a pharmaceutically acceptable salt thereof). “Treating” includes inhibiting the disease orAttorney Docket No. 01367-0015-00PCTcondition (e.g., as by slowing or stopping its progression or causing regression of the disease or condition), and relieving the symptoms resulting from the disease or condition.

[0050] “A therapeutically effective amount’’ is an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., induction of immune tolerance, reduction of immune intolerance, treatment, healing, inhibition or amelioration of physiological response or condition, etc.). The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses Thus, a therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount may vary according to factors such as disease state, age, sex, and weight of a mammal (such as a human), mode of administration and the ability of a therapeutic, or combination of therapeutics, to elicit a desired response in an individual.

[0051] As used herein, “subject” includes humans, domestic animals, such as laboratory¬ animals (e.g., dogs, monkeys, pigs, rats, mice, etc.), household pets (e.g., cats, dogs, rabbits, etc.) and livestock (e.g., pigs, cattle, sheep, goats, horses, etc.), and non-domestic animals. In some aspects, a subject is a mammal. In some aspects, a subject is a human.

[0052] As used herein, an “eczema area and severity index (EASI) score” refers to clinician-reported outcome (ClinRO) assessing the extent of atopic dermatitis at four body regions (head and neck, trunk, and upper and lower extremities) by measuring the average severity of four clinical signs at each body region: (I) erythema, (2) induration / papulation. (3) excoriation, and (4) lichenification, each on a scale of 0 (absent) to 3 (severe). To calculate an EASI score, the sum of the severity scores for each region is multiplied by a region score (a value of between 0 to 6 representing the percentage of skin affected by eczema), and finally is weighted by a body region dependent multiplier (0.1 for head / neck.0.3 for trunk, 0.2 for upper extremities, and 0.4 for lower extremities). This provides an EAST score per body region, with the final EASI score being the sum of the four region scores. The minimum EASI score is 0 and the maximum EASI score is 72, with a higher score indicating a higher (worse) severity of AD.

[0053] As used herein, “validated investigator’s global assessment scale (vIGA) score” refers to a one-item static ClinRO that uses a five-point scale from 0 (clear) to 4 (severe) based on four clinical features for atopic dermatitis lesions: erythema, induration / papulation, lichenification, and oozing / crusting, and taking extent of disease into account.

[0054] As used herein, “percent body surface area (BSA) involvement” refers to the percentage of the surface area of a body region exhibiting atopic dermatitis involvement.Attorney Docket No. 01367-0015-00PCTBSA affected by atopic dermatitis is assessed for each section of the body, e.g., using the rule of nines. The possible highest score for each region is: head and neck: 9%; anterior trunk: 18%; back: 18%; upper limbs: 18%; lower limbs: 36%; genitals: 1%. Affected BSA is reported as a percentage of all regions combined.

[0055] As used herein, “pruritic numerical rating scale (NRS) score” refers to a patient- reported scale used to measure the severity of itch. Patients rate their itch on a scale of 0 to 10. where 0 is “no itch” and 10 is “worst itch imaginable.” The rating is based on the worst itch the patient experienced in the previous 24 hours.B. Overview

[0056] The present disclosure provides methods of treating a T helper 2 (Th2) cell- mediated disorder. The methods comprise administering to a subject in need thereof a compound of the disclosure (e.g., a therapeutically effective amount of a compound of the disclosure).

[0057] Without wishing to be bound by a particular theory, compounds described herein for use m the disclosed methods engage and modulate (e.g.. activate) the T-cell immunoglobulin mucin protein (TIM) family of receptors. V anous compounds of the present disclosure are capable of binding TIM, e.g, with higher affinity than its natural ligand, phosphatidyl serine, and diminishing the immune response. TIM receptors are type I cellsurface gly coproteins, and TIM1, TIM3. and TIM4 TIM receptors, expressed in humans, have been identified as phosphatidylserine receptors. TIM1 is preferentially expressed on T-helper 2 cells, and operates as a potent costimulatory' molecule for T-cell activation. TIM3 is preferentially expressed on T-helper 1 cells, ty pe 1 T-cells and dendritic cells, and generates an inhibitory signal resulting in apoptosis of T-helper 1 cells and type 1 T-cells. TIM4 is expressed on antigen-presenting cells, and mediates phagocytosis of apoptotic cells, thereby promoting tolerance In some aspects, the TIM receptor is a TIM3 receptor. In some aspects, the TIM receptor is a TIM4 receptor. In some aspects, the TIM receptor is a TIM1 receptor. “TIM” is also referred to, for example, in the literature, as “Tim.”

[0058] Agonists of TIM receptors inhibit the activity of at least toll-like receptor (TLR) 3 and TLR7. without substantially inhibiting the activity of TLRs 2 and 4, which largely recognize patterns presented by bacteria. Toll-like receptors (TLRs) form a family of pattern recognition receptors that are expressed on innate immune cells, and constitute the immune system’s first line of defense against microbes. To date, ten human subtypes of TLRs have been identified. TLRs 1, 2, 4, 5. 6 and 10 are expressed on the cell surface, and TLRs 3. 7, 8 and 9 are localized to the endoplasmic reticulum, endosomes and lysosomes. TLRs 1, 2 and 6Attorney Docket No. 01367-0015-00PCTrecognize and bind to bacterial lipoproteins and glycolipids. TLRs 3, 7, 8 and 9 recognize and bind to nucleic acids, such as viral dsRNA (TLR3), ssRNA (TLR7. TLR8) and unmethylated CpG DNA (TLR9). TLR4 recognizes and binds to fibronectin and LPS. TLR5 recognizes and binds to bacterial flagellin. Without wishing to be bound by any particular theory, it is believed that compounds of the disclosure do not result in general immunosuppression, but may exert their effects in a more selective and specific manner.

[0059] In some embodiments, the compound administered in the disclosed methods selectively modulates (e.g, inhibits) the activity of TLR3, TLR7, TLR8 and / or TLR9, e.g., modulates (e.g., inhibits) the activity of TLR3, TLR7, TLR8 and / or TLR9 to a greater extent than it modulates the activity of TLRs 1, 2, 4, 5, 6 and / or 10. For example, modulation (e.g., inhibition) of the activity of TLR3, TLR7, TLR8 and / or TLR9 by a compound of the disclosure can be more than two-fold greater, e.g.. more than five-fold, more than 10-fold, more than 25-fold or more than 100-fold greater, than modulation (e.g., inhibition) of the activity of TLRs 1, 2, 4, 5, 6 and / or 10 by the compound. In some aspects, the compound does not modulate (e.g., inhibit) the activity of TLRs 1, 2. 4, 5, 6 and / or 10 to a measurable extent.

[0060] A compound administered to a subject having a disease, disorder or condition described herein in a method disclosed herein may, for example, modulate TLR activity (such as selectively modulate TLR3, TLR7, TLR8 and / or TLR9 activity) in an immune cell, e.g.. a T-cell, such as a regulatory T-cell, a natural killer (NK) cell, a macrophage, a neutrophil, a myeloid-derived suppressor cell or a dendritic cell In some aspects, an immune cell is FoxP3+ and / or CD4+, such as a FoxP3+ and / or CD4+ T-cell of the subject In some aspects, the immune cell is a B-cell, such as a regulatory B-cell. In some aspects, an immune cell (e.g, regulatory B-cell) is CDI9+, CD71+. IgMT CD24+, CD38+ and / or CD27+.

[0061] Administration of a compound disclosed herein to a subject in a method described herein may induce in the subject a measurable immune response, e.g., to an antigen, such as measurable antibody production in response to an antigen. In some aspects, a subject does not have a measurable immune response, e.g., to an antigen, such as measurable antibody production in response to an antigen. ELISA and / or activity assays, including those described herein, are known m the art, and can be used to measure antibody production

[0062] In some embodiments, administration of a compound of the disclosure to a subject in need thereof leads to expansion of natural regulatory T-cells in the subject. Such treatment does not interfere with innate immune response, such as that mounted by innate immune cells responding to danger signals from pathogens, but results in general adaptiveAttorney Docket No. 01367-0015-00PCTimmunotolerization, which can be achieved herein without general innate immune suppression, such that, for example, a subject can still mount an innate immune response to an antigen (e.g., pathogen).

[0063] In a subject, administration of a compound disclosed herein using a method described herein may result in (a) absence and / or diminishment of immunological hyperactivity and / or anti-inflammatory cytokine release; (b) neutralization of immune cells such as macrophages, neutrophils, eosinophils, T-cells and B-cells; (c) an increase in number of regulatory T-cells and / or m the activity or level of tolerogenic T-cells (e.g., FoxP3+ / CD4+ T-cells; CD4+ / CD25hi / FoxP3+ / CTLA4+ / Tim3+ / NRP1+ / ICOS- T-cells;CD4+ / CD25hi / FoxP3+ / CTLA4+ / Tim3+ T-cells; and / or CD4+ / CD25hi / FoxP3+ / CTLA4+ / NRP1+ / ICOS- T-cells); and / or (d) an increase in the number of regulatory B-cells (e.g., CD19+ / CD71+ / IgM-i- / CD24+ / CD38->- / CD27+ B-cells; and / or CD19-’7CD71 ’- / IgM-i- B-cells). Techniques for evaluating these indicators (e.g., of general immunotolerization) are known in the art and described herein. For example, certain of the aforementioned indicators can be evaluated using culture conditions.

[0064] In some embodiments of the disclosed methods, administering a compound described herein to a subject results in induction of a population of regulatory T cells in the subject Without wishing to be bound by any particular theory-, it is believed that the compounds of the disclosure induce a population of regulatory T-cells primarily by¬ expanding the population of natural regulatory T-cells (nTregs, e.g., regulatory- T-cells which are FoxP3+ / NRPl+). The compounds described herein also induce or upregulate inducible regulatory T-cells (iTregs, e.g, FoxP3+ T-cells. FoxP3+ / TIM3+ T-cells). Accordingly, inducing a population of regulatory- T-cells can comprise expanding a population of natural regulatory T-cells (e.g., regulatory T-cells which are FoxP3+ / NRPl+), for example, without substantially inducing inducible regulatory- T-cells in the subject. Neuropilin-1 (Nrpl) expression can be used to distinguish between natural and inducible regulatory T-cells, for example, as described herein. Thus, inducing a population of regulatory T-cells can comprise inducing a population of regulatory T-cells expressing Nrp1 (e.g., FoxP3+ / NRPl+ T-cells) as, for example, by expanding a population of natural regulatory T-cells. Without wishing to be bound by any particular theory, it is expected that the ability to expand a population of natural regulatory T-cells (e.g., regulatory T-cells which are FoxP3+ / NRP1+), for example, without substantially inducing inducible regulatory- T-cells, will not affect general immunosuppression.Attorney Docket No. 01367-0015-00PCT

[0065] In some aspects, regulatory' T-cells are FoxP3+, e.g, FoxP3+ / TIM3+, FoxP3+ / NRPl+. Whether a regulatory' T-cell is positive (+) or negative (-) for any of the aforementioned markers can be determined, for example, by flow cytometry analysis.C. Methods of Use

[0066] The present disclosure provides methods of treating a T helper 2 (Th2) cell-mediated disorder, comprising administering to a subject in need thereof a compound of the disclosure.

[0067] Certain methods of the present disclosure comprise administering to a subject in need thereof a compound having the following structural formulaor a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing, wherein: Ring A is phenyl or (C5-C6)heteroaryl;L is -(CH2)n-, -C(O)- or -C(OH)2-;R1is H or (C1-C5)alkyl;each R2is independently chloro or fluoro;R3is (C1-C3)alkyl substituted with one or more independently selected (C6-C15)aryl or (C5-C15)heteroaryl, wherein the (C6-C15)aryl and (C5-C15)heteroaryl are each independently substituted with -(R30)p;each R30is independently halo, (C1-C5)alkoxy, (C1-C5)haloalkoxy, (C1-C5)alkyl or (C1-C5)haloalkyl, or two R30attached to adjacent ring atoms, taken together, form -(CH2)q- or -O(CH2)rO-;n is 1, 2 or 3:m is 0, 1, 2, 3 or 4;each p is independently 0, 1, 2, 3, 4, 5, 6. 7, 8, 9 or 10;each q is independently 3, 4, 5 or 6; andeach r is independently 1, 2, 3 or 4.

[0068] in some aspects of structural formula (I), Ring A is phenyl or pyridinyl. In some aspects. Ring A is phenyl.

[0069] In some aspects of structural formula (I). R1is H

[0070] In some aspects, R3is methyl substituted with one, two or three independently selected (C6-C15)aryl or (C5-C15)heteroaryl, each independently substituted with -(R30)p. InAttorney Docket No. 01367-0015-00PCTsome aspects, R3is (Ci-Csjalkyl (and, in some preferred aspects, methyl) substituted with one or more (e.g., one, two or three) independently selected (Ce-Cisjaryl or (Cs-Cislheteroaryl independently selected from phenyl, naphthyl, pyndinyl, quinolinyl, isoquinolinyl or benzo[ ]imidazolyl, each independently substituted with -(R30)p. In some aspects, R3is (Ci-Csjalkyl (and, in some preferred aspects, methyl) substituted with one or two independently selected (Cs-Cisjaryl or (C's-Cis heteroaiyl (and, in some preferred aspects, a (Ce-Cisjaryl or (C5-Ci5)heteroaryl independently selected from phenyl, naphthyl, pyridinyl, quinolinyl. isoquinolinyl or benzo [<7] imidazolyl), each independently substituted with -(R30)p.

[0071] In some aspects of structural formula (I), n is 1. In some aspects, n is 1 or 2. In some aspects, m is 0. In some aspects, each p is independently 0, 1, or 2. In some aspects, each q is independently 3 or 4. In some aspects, each r is independently 1 or 2,

[0072] In some aspects of structural formula (I), the -OR? is attached to the ring atom of Ring A which is meta or para to L. Tn some aspects, the -OR3is attached to the ring atom of Ring A which is para to L.

[0073] Certain methods of the present disclosure compnse administering to a subject in need thereof a compound having the following structural formula:or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. Values for the variables (e.g., Ring A, R1, R2, R3, n, m) are as described with respect to structural formula (I), or any aspect or combination of aspects thereof.

[0074] In some aspects of structural formula (II), the -OR3is attached to the ring atom of Ring A which is meta or para to -(CH2)n-. In some aspects, the -OR3is attached to the ring atom of Ring A which is para to -(CH2)n-.

[0075] Certain methods of the present disclosure comprise administering to a subject in need thereof a compound having the following structural formula:or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing, wherein; X1, X2and X3are each C(H);Attorney Docket No. 01367-0015-00PCTX1is N, and X2and X3are each C(H);X1and X2are each C(H), and X3is N; orX1and X3are each C(H), and X2is N.Values for the remaining variables (e.g, R1, R2, R \ n, m) are as described with respect to structural formula (I), or any aspect or combination of aspects thereof

[0076] In some aspects of structural formula (III), X1, X2and X3are each C(H). In alternative aspects. X1is N, and X2and X3are each C(H).

[0077] In some aspects of structural formula (III), the -OR3is attached to the ring atom of Ring A which is meta or para to -(CHi)n-. In some aspects, the -OR3is attached to the ring atom of Ring A which is para to -(CH2)n-.

[0078] Examples of compounds of Structural Formula I include the compounds listed in Table 1, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. In some aspects, a compound of Structural Formula I is selected from the compounds listed in Table 1, or a pharmaceutically acceptable salt thereof. Methods of making compounds of the disclosure are described, for example, in International Publication No. WO 2023 / 019244 and US Patent Appln. Publication No. US 2023 / 0089267. the entire contents of which are incorporated herein by referenceAttorney Docket No. 01367-0015-00PCT

[0079] In some embodiments of the disclosed methods, a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof is administered to a subject in need thereof. In some embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered when the Th2 cell-mediated disorder is active. In some embodiments, administration of the compound, or pharmaceutically acceptable salt thereof, is discontinued during remission of the Th2 cell-mediated disorder. In some embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered when the Th2 cell-mediated disorder is active and is discontinued during remission of the disorder.

[0080] In some aspects, a disorder (e.g., a Th2 cell-mediated disorder) is previously untreated. In some aspects, a disorder is previously treated, e.g., with a disease-modifying therapy.Attorney Docket No. 01367-0015-00PCT

[0081] In some embodiments, prior to the treatment with the compound, or pharmaceutically acceptable salt thereof, the subject had an inadequate response to and / or experienced a grade 2 or greater adverse event related to a systemic or topical disease¬ modifying therapy for the Th2 cell-mediated disorder. In some embodiments, the inadequate response and / or the grade 2 or greater adverse event comprises skin atrophy, an allergic reaction, or a systemic effect that outweighed the benefits of the therapy. In some embodiments, the disease-modifying therapy comprises atopical corticosteroid, topical immune modulator, a topical phosphodiesterase type 4 (PDE 4) inhibitor, a topical JAK inhibitors, a topical aryl hydrocarbon receptor agonist, a topical or systemic antihistamine, an emollient, an oral systemic immunosuppressive and / or immunomodulating therapy, a cell depleting therapy, dupilumab, tralokinumab, ustekinumab, secukinumab. ixikizumab, an anti-TNF inhibitor, PUVA phototherapy, or UVB phototherapy.

[0082] Some embodiments of the disclosed methods further comprise administering to the subject an additional therapeutic. A compound of the disclosure can be administered before, after or concurrently with an additional therapeutic. When administered simultaneously (e.g., concurrently), the compound of the disclosure and additional therapeutic can be in separate formulations or the same formulation. Alternatively, the compound of the disclosure and additional therapeutic can be administered sequentially, either at approximately the same time or at different times, as separate compositions. When the compound of the disclosure and the additional therapeutic are administered as separate formulations or compositions, the compound of the disclosure and the additional therapeutic can be administered by the same route of administration or by different routes of administration. A skilled clinician can determine appropriate timing for administration of each therapy being used in combination (e.g, timing sufficient to allow an overlap of the pharmaceutical effects of the therapies). A combination therapy may provide beneficial effects of the drug combination in treating a Th2 cell-mediated disorder described herein

[0083] In some aspects, the compound of the disclosure or composition described herein is administered before the additional therapeutic. In some aspects, the compound of the disclosure or composition described herein is administered after the additional therapeutic. In some aspects, the compound of the disclosure or composition described herein is administered concurrently with the additional therapeutic.

[0084] In some embodiments, the additional therapeutic is a disease-modifying therapy. Thus, some embodiments of the disclosed methods further comprise administering to the subject a disease-modifying therapy.Attorney Docket No. 01367-0015-00PCT

[0085] A therapeutically effective amount of an agent to be administered can be determined by a clinician of ordinary skill using the guidance provided herein and other methods known in the art. For example, suitable dosages can be from about 0.001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 10 mg / kg, from about 0.01 mg / kg to about 1 mg / kg body weight per administration. Determining the dosage for a particular agent, subject and disease is well within the abilities of one of skill in the art. Preferably, the dosage does not cause or produces minimal adverse side effects.

[0086] A compound of the disclosure, composition described herein, or other therapeutic agent can be administered via a variety of routes of administration, including, for example, oral, dietary, topical, transdermal, rectal, parenteral (e.g, intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection), intravenous infusion and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the compound and / or therapeutic agent, respectively, and the particular disease. Administration can be local or systemic as indicated. The preferred mode of administration can vary' depending on the particular compound or agent.

[0087] Administration of a compound or composition for use in the disclosed methods can be local or systemic as indicated. In some embodiments, administration (e.g., of a compound of the disclosure) is oral. In some embodiments, administration (e.g., of a compound of the disclosure) is intravenous. Tire preferred mode of administration can vary’ depending on the particular compound or agent. In some embodiments, a compound of the disclosure or other therapeutic agent will be administered from about 1 to about 6 (e.g, 1, 2, 3, 4, 5 or 6) times per day' orally.

[0088] In some embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered to the subject in need thereof daily. In some embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered to the subject in need thereof once per day, twice per day, more than twice per day, once every two days, once every three days, once every four days, once every five days, once every six days, once every seven days, or less than once every seven days. In some aspects, the compound, or pharmaceutically acceptable salt thereof, is administered to the subject m need thereof QD or BID (e.g., QD) In particular embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered to the subject in need thereof once daily (QD).

[0089] A compound or other therapeutic agent for use in the disclosed methods can be administered in a dosage ranging from about 0.001 mg / kg to about 100 mg / kg of body weightAttorney Docket No. 01367-0015-00PCTor, alternatively, in a dosage ranging from about 1 mg / dose to about 5,000 mg / dose, every 4 to 120 hours, or according to the requirements of the particular agent. For example, suitable dosages can be from about 0.001 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 100 mg / kg, from about 0.01 mg / kg to about 10 mg / kg, from about 0.01 mg / kg to about 1 mg / kg body weight per treatment. In some aspects, a suitable dosage (e.g., daily dosage) is from about 0.1 mg / kg to about 10 mg / kg, e.g.. from about 0.1 mg / kg to about 5 mg / kg. from about 0.1 mg / kg to about 2.5 mg / kg or about 0.2 mg / kg to about 2.4 mg / kg, body weight per treatment. Suitable dosages can be from about 0.001 mg / dose to about 100 mg / dose, from about 0.01 mg / dose to about 100 mg / dose, from about 0.1 mg / dose to about 50 mg / dose, from about 0.1 mg / dose to about 10 mg / dose, from about 0.5 mg / dose to about 50 mg / dose, from about 1 mg / dose to about 10.000 mg / dose. from about 1 mg / dose to about 7,500 mg / dose, from about 1 mg / dose to about 5.000 mg / dose. from about 10 mg / dose to about 2,500 mg / dose or from about 100 mg / dose to about 1,000 mg / dose. In some aspects, a suitable dosage (e.g, daily dosage) is from about 10 mg / dose to about 1,000 mg / dose, e.g, from about 15 mg / dose to about 1.000 mg / dose. from about 10 mg / dose to about 500 mg / dose. from about 10 mg / dose to about 250 mg / dose, from about 15 mg / dose to about 150 mg / dose, about 15 mg / dose, about 30 mg / dose, about 50 mg / dose, about 100 mg / dose, about 125 mg / dose or about 150 mg / dose.

[0090] Doses lower or higher than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend, for example, upon a variety of factors, such as the activity of the specific agent employed, the age. body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the seventy' and course of the disease, condition or symptoms, the subject's disposition to the disease, condition or symptoms, and the judgment of the treating physician. Determining the dosage for a particular agent, subject and disease, disorder or condition is within the abilities of one of skill in the art.

[0091] In some embodiments of the disclosed methods, the Th2 cell-mediated disorder is atopic dermatitis (eczema), allergic asthma, graft versus host disease, progressive systemic sclerosis (scleroderma), rhinosinusitis, prurigo nodularis, an eosinophilic gastrointestinal disorder, a systemic allergic reaction, a hypereosinophilic syndrome, or another Th2-mediated allergy’, such as a food allergy. In some embodiments of the disclosed methods, the Th2 cell-mediated disorder is atopic dermatitis (eczema), allergic asthma, graft versus host disease, progressive systemic sclerosis (scleroderma), rhinosinusitis, prurigo nodularis, or anAttorney Docket No. 01367-0015-00PCTeosinophilic gastrointestinal disorder, a systemic allergic reaction, or a hypereosinophilic syndrome.

[0092] In a particular embodiment, the Th2-mediated disorder is atopic dermatitis (eczema). In some such embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an eczema area and seventy index (EASI) score of less than or equal to 72, less than or equal to 60, less than or equal to 50. less than or equal to 40, less than or equal to 30, less than or equal to 25, less than or equal to 20. less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16, less than or equal to 15, less than or equal to 14, less than or equal to 13, less than or equal to 12, less than or equal to 11. less than or equal to 10, less than or equal to 5, or zero. In some such embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an eczema area and seventy index (EASI) score of less than or equal to 30, less than or equal to 25, less than or equal to 20, less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16. less than or equal to 15, less than or equal to 14, less than or equal to 13. less than or equal to 12, less than or equal to 11, less than or equal to 10, less than or equal to 5, or zero. In particular embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score of less than or equal to 16.

[0093] In some embodiments, prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score of greater than or equal to 16 In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score that is at least 20 percent lower, at least 25 percent lower, at least 30 percent low'er, at least 35 percent lower, at least 40 percent lower, at least 45 percent lower, at least 50 percent lower, at least 55 percent low er, at least 60 percent lower, at least 65 percent low-er, at least 70 percent lower. or at least 75 percent low er than an EASI score of the subject at day 0 of the treatment period. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score that is at least 20 percent lower than an EASI score of the subject at day 0 of the treatment period.

[0094] In some embodiments, following 28 days of treatment w ith the compound, or the pharmaceutically acceptable salt thereof, the subject has a validated investigator's global assessment scale (vIGA) score of less than or equal to 4, less than or equal to 3, less than or equal to 2, less than or equal to I, or 0. In some embodiments, following 28 days of treatmentAttorney Docket No. 01367-0015-00PCTwith the compound, or the pharmaceutically acceptable salt thereof, the subject has a validated investigator’s global assessment scale (vIGA) score of less than or equal to 2, less than or equal to 1, or 0. In some embodiments, prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a vIGA score of greater than or equal to 3. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a vIGA score that is at least 20 percent lower, at least 25 percent lower, at least 30 percent lower, at least 35 percent lower, at least 40 percent lower, at least 45 percent lower. at least 50 percent lower, at least 55 percent lower, at least 60 percent lower, at least 65 percent lower, at feast 70 percent lower, or at least 75 percent lower than a vIGA score of the subject at day 0 of the treatment period. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a vIGA score that is at least 20 percent lower than a vIGA score of the subject at day 0 of the treatment period.

[0095] In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a pruritic numerical rating scale (NRS) score of less than or equal to 10, less than or equal to 9, less than or equal to 8, less than or equal to 7, less than or equal to 6, less than or equal to 5, less than or equal to 4, less than or equal to 3, less than or equal to 2, less than or equal to 1, or zero. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a pruritic numerical rating scale (NRS) score of less than or equal to 6, less than or equal to 5, less than or equal to 4, less than or equal to 3, less than or equal to 2, less than or equal to 1, or zero. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a pruritic numerical rating scale (NRS) score of less than or equal to 4.

[0096] In some embodiments, prior to treatment with the compound, or the pharmaceutically acceptable salt thereof the subject has an NRS score of greater than or equal to 4. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an NRS score that is at least 20 percent lower, at least 25 percent lower, at least 30 percent lower, at least 35 percent lower, at least 40 percent lower, at least 45 percent lower, at least 50 percent lower, at least 55 percent lower, at least 60 percent lower, at least 65 percent lower, at least 70 percent lower, or at least 75 percent lower than an NRS score of the subject at day 0 of the treatment period.

[0097] In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent body surface area (BSA)Attorney Docket No. 01367-0015-00PCTinvolvement of less than or equal to 100%, less than or equal to 90%, less than or equal to 80%, less than or equal to 70%, less than or equal to 60%, less than or equal to 50%, less than or equal to 40%, less than or equal to 30%, less than or equal to 20%, less than or equal to 15%, less than or equal to 14%, less than or equal to 13%, less than or equal to 12%, less than or equal to 11%, less than or equal to 10%, less than or equal to 9%, less than or equal to 8%, less than or equal to 7%, less than or equal to 6%, less than or equal to 5%, less than or equal to 4%, less than or equal to 3%, less than or equal to 2%, or less than or equal to 1%. In particular embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent body surface area (BSA) involvement of less than or equal to 10%.

[0098] In some embodiments, prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent BSA of greater than or equal to 10%. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent BSA that is at least 20 percent lower, at least 25 percent lower, at least 30 percent lower, at least 35 percent lower, at least 40 percent lower, at least 45 percent lower, at least 50 percent lower, at least 55 percent lower, at least 60 percent lower, at least 65 percent lower, at least 70 percent lower, or at least 75 percent lower than a percent BSA of the subject at day 0 of the treatment period. In some embodiments, following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent BSA that is at least 20 percent lower than a percent BSA of the subject at day 0 of the treatment period.D. Compositions for Use in the Disclosed Methods

[0099] Some embodiments of the present disclosure comprise administering to the subject a therapeutically effective amount of a compound described herein, e.g, in the form of a composition described herein. Typically, for administration to a subject, a compound of the disclosure is formulated with one or more pharmaceutically acceptable carriers. The disclosure provides such compositions, including pharmaceutical compositions. Thus, one embodiment is a composition (e.g, pharmaceutical composition) comprising a compound of the disclosure and a pharmaceutically acceptable carrier. I’he compositions described herein can be used in the methods described herein, e.g., to supply a compound of the disclosure.

[0100] Compounds and compositions for use in the methods described herein can also be in the form of formulations of lipid particles, such as liposomal formulations. Thus, one embodiment is a lipid particle (e.g, a liposome) comprising one or more lipids and a compound of the disclosure.Attorney Docket No. 01367-0015-00PCT

[0101] Also provided herein is a solid lipid particle (e.g., liposome) comprising at least one phospholipid (e.g. a phospholipid containing a C4-C30 acyl chain, such as a saturated C4-C30 acyl chain, as in dimyristoylphosphatidylcholine (DMPC)) and a therapeutic agent e.g., a compound of the disclosure) that can embed in a lipid bilayer of the lipid particle. It has been found that oral administration of such solid lipid particles can be used to target the lipid particle (and thereby the therapeutic agent) to immune cells and / or lymph node(s), for example, and thereby enhance colocalization of the lipid particles and immune cells (e.g., in the lymph nodes) and / or enhance lymph node uptake of the lipid particles.

[0102] As used herein, “lipid particle’’ refers to a particle comprising at least one lipid, e.g., a phospholipid, such as a lysophospholipid. Examples of lipid particles include, liposomes, micelles and lipid nanoparticles. Lipid particles, such as liposomes, can be unilamellar or multilamellar. Lipid particles, such as liposomes, can have fluidic lipid membranes, or gel-like or solid lipid membranes, for example, lipid membranes that melt above normal body temperature of a human, or about 37 °C. In some aspects, a lipid particle is a liposome. In some aspects, a lipid particle is a lipid nanoparticle. In some aspects, a lipid particle is solid. In some aspects, a lipid particle has a melting temperature above about 37 °C, e.g., above about 40 °C, above about 45 °C, above about 50 °C, above about 55 °C or about 55 °C.

[0103] Examples of phospholipids include dimyristoylphosphatidylcholine (DMPC). 1,2-dioleoyl-sn-glycero-3-phosphocholine 18:1 A9-Cis PC (DOPC), l,2-distearoyl-sn-glycero-3-phosphocholine 18:0 (DSPC), l-palmitoyl-2-oleoyl-glycero-3-phosphocholine 16:0-18: 1 (POPC), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine, phosphatidyl inositol, bisphosphatidyl glycerol, phosphatidic acid, phosphatidyl alcohol and phosphatidyl glycerol. Phospholipids can be saturated or unsaturated, i.e., contain one or more units of unsaturation, and can contain acyl chains of a variety of lengths. In some aspects, a phospholipid contains a C₄-C₃₀ acyl chain, e.g., a C₈-C₂₆, C₁₂-C₂₂, C₁₀-C₂₅, C₁₄-C₁₈ or C₁₆-C₂₆ acyl chain. Phospholipids can be obtained from various sources, both natural and synthetic. For example, PS can be obtained from porcine brain PS or plant-based soy (so a bean) PS. Egg PC and PS and synthetic PC are available commercially. In some aspects, a phospholipid is not PS, or a salt thereof (e.g., pharmaceutically acceptable salt thereof)

[0104] Other lipids suitable for inclusion in the lipid particles described herein include N4-cholesteryl-spermine, or a salt thereof, such as N4-cholesteryl -spermine HCl salt. N4-cholesteryl-spermine HCl salt is also known as Genzyme Lipid 67 (GL67). and is a cholesterol derivatized with spermine to create a cationic lipid HCl salt.Attorney Docket No. 01367-0015-00PCT

[0105] Typically, the molar percentage of a therapeutic agent (e.g., a compound described herein for use in the methods disclosed herein) in a lipid particle (e.g., liposome) comprising the therapeutic agent will be from about 1% to about 50%, e.g., from about 1% to about 35%, from about 1% to about 25%, from about 1% to about 15%, from about 3% to about 10%, from about 5% to about 50%, from about 5% to about 45%, from about 15% to about 40%. from about 25% to about 35%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%. about 7%, about 8%, about 9%, about 10%. about 15%, about 25%, about 30% or about 35%. In some aspects, the molar percentage of a therapeutic agent (e.g, compound of the disclosure) in a lipid particle (e.g., liposome) comprising the therapeutic agent will be less than 35%, e.g., less than 30%, less than 15%, or from about 1% to about 10%.

[0106] Typically, the molar percentage of lipid (taken individually or collectively) in a lipid particle (e.g., liposome) described herein will be from about 50% to about 99%, e.g., from about 50% to about 75%, from about 85% to about 99%, about 70%, about 75%, about 85%, about 90%. about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%. The molar percentage of each lipid in a lipid particle (e.g., liposome) described herein can be from about 1% to about 99%, e g, from about 1 % to about 50%, from about 1% to about 35%, from about 1% to about 25%, from about 1% to about 15%. from about 3% to about 10%, from about 5% to about 50%, from about 5% to about 45%. from about 15% to about 40%, from about 25% to about 35%, about 1%. about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%. about 15%, about 25%, about 30% or about 35%.

[0107] A compound disclosed herein can be encapsulated within a lipid particle, such as a liposome, described herein, bound (covalently or non-covalently) to a lipid head group or, preferably, embedded, in whole or in part, covalently or non-covalently, in a lipid bilayer (e.g, of a liposome). Without wishing to be bound by any particular theory, it is believed that compounds of the disclosure may embed in a lipid bilayer of a liposome so as to leave the amino acid residue of the compound of the disclosure exposed to the exterior of the liposome, thereby mimicking the natural surface presentation of, for example, PS.

[0108] In some aspects, the one or more lipids comprises a phospholipid, or a pharmaceutically acceptable salt thereof, e.g., l,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC). or a pharmaceutically acceptable salt thereof. In some aspects, the phospholipid is a saturated phospholipid, e.g., a saturated phospholipid containing a C4-C30 acyl chain. In some aspects, the phospholipid is unsaturated, e.g., an unsaturated phospholipid containing aAttorney Docket No. 01367-0015-00PCTC₄-C₃₀ acyl chain. In some aspects, the phospholipid is selected from DMPC, DSPC, DOPC or POPC, or a pharmaceutically acceptable salt of the foregoing. In some aspects, the phospholipid is DMPC or DSPC, or a pharmaceutically acceptable salt of the foregoing.

[0109] Lipid particles described herein can be formulated for oral and / or parenteral (e.g., subcutaneous, intramuscular, intravenous, intradermal) administration, e.g., as by injection.

[0110] Some embodiments of the disclosed methods comprise administering to a subject in need thereof a therapeutically effective amount of a composition (e.g., pharmaceutical composition) comprising a plurality of lipid particles (e.g., a plurality of lipid particles comprising a compound of the disclosure). In some aspects, a composition further comprises a pharmaceutically acceptable carrier.

[0111] Compositions for use in the methods described herein and, hence, compounds of the disclosure, may be administered orally, parenterally (including subcutaneously, intramuscularly, intravenously and intradermally), by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The terms “parenteral’’ and “parenterally,” as used herein, include subcutaneous, intracutaneous, intravenous, intramuscular, intraocular, intravitreal, intra-articular, intra-arterial, intra-synovial, intrastemal, intrathecal, intralesional, intrahepatic, intraperitoneal, intralesional and intracranial injection or infusion techniques. In some aspects, a composition described herein is administrable intravenously and / or intraperitoneally. In some aspects, a composition described herein is administrable orally. In some aspects, a composition described herein is administrable subcutaneously. Preferably, a composition described herein is administered orally, subcutaneously, intraperitoneally, or intravenously.

[0112] C ompositions for use in the methods provided herein can be orally administered in any orally acceptable dosage form including, but not limited to. capsules, tablets, aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers commonly- used include lactose and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions and / or emulsions are required for oral use, the active ingredient can be suspended or dissolved in an oily phase and combined with emulsifying and / or suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0113] In some embodiments, an oral formulation is formulated for immediate release or sustained / delayed release.Attorney Docket No. 01367-0015-00PCT

[0114] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or (a) fillers or extenders such as starches. lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, algmic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium salts, (g) wetting agents, such as acetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0115] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to compounds of the disclosure, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol (ethanol), isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol. 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty' acid esters of sorbitan, or mixtures thereof. Besides inert diluents, oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

[0116] Compositions suitable for buccal or sublingual administration as part of the disclosed methods include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

[0117] Solid compositions of a similar ty pe may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally,Attorney Docket No. 01367-0015-00PCTin a delayed manner. Examples of embedding compositions that can be used in the disclosed methods include polymeric substances and waxes.

[0118] A compound of the disclosure can also be in micro-encapsulated form with one or more excipients, as noted above. In such solid dosage forms, the compound can be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g.. tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.

[0119] Compositions for oral administration may be designed to protect the active ingredient against degradation as it passes through the alimentary’ tract, for example, by an outer coating of the formulation on a tablet or capsule.

[0120] In another aspect, a compound for use in the disclosed methods can be provided in an extended (or "delayed” or “sustained”) release composition. This delayed-release composition comprises the compound of the disclosure and a delayed-release component. Such a composition allows targeted release of the compound, for example, into the lower gastrointestinal tract, for example, into the small intestine, the large intestine, the colon and / or the rectum. In certain aspects, a delayed-release composition further comprises an enteric or pH-dependent coating, such as cellulose acetate phthalates and other phthalates (e.g., polyvinyl acetate phthalate, methacrylates (Eudragits)). Alternatively, the delayed-release composition can provide controlled release to the small intestine and / or colon by the provision of pH sensitive methacrylate coatings, pH sensitive polymeric microspheres, or polymers which undergo degradation by hydrolysis. The delayed-release composition can be formulated with hydrophobic or gelling excipients or coatings. Colonic delivery can further be provided by coatings which are digested by bacterial enzymes such as amylose or pectin, by pH dependent polymers, by hydrogel plugs swelling with time (Pulsincap), by time¬ dependent hydrogel coatings and / or by acrylic acid linked to azoaromatic bonds coatings.

[0121] Compositions for use in the methods described herein can also be administered subcutaneously, intraperitoneally or intravenously, e.g., in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example. Tween 80) and suspending agents The sterile injectable preparation can also be a sterile injectable solution or suspension in a non¬ toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, dextrose, water, Ringer’s solution, lactated Ringer’s solution and isotonic sodium chloride solution. InAttorney Docket No. 01367-0015-00PCTaddition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and / or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purposes of formulation.

[0122] Compositions described herein can also be administered in the form of suppositories for rectal administration. These can be prepared by mixing a compound of the disclosure with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and, therefore, will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0123] Compositions described herein can also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0124] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically- transdermal patches can also be used.

[0125] For other topical applications, compositions for use in the disclosed methods can be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of a compound described herein include, but are not limited to, mineral oil. liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, poly oxypropylene compound, emulsifying wax and water and penetration enhancers. Alternatively, compositions can be formulated in a suitable lotion or cream containing the active compound suspended or dissolved in one or more pharmaceutically acceptable carriers. Alternatively, the composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil.Attorney Docket No. 01367-0015-00PCTsorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyi alcohol, 2-octyldodecanol, benzy l alcohol and water. Suitable carriers also include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyi alcohol, 2-octyldodecanol, benzyl alcohol and water and penetration enhancers.

[0126] For ophthalmic use, compositions can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic use. the compositions can be formulated in an ointment such as petrolatum.

[0127] Compositions can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents. Without wishing to be bound by any particular theory, it is believed that local delivery of a composition described herein, as can be achieved by nasal aerosol or inhalation, for example, can reduce the risk of systemic consequences of the composition, for example, consequences for red blood cells.

[0128] Other pharmaceutically acceptable carriers that can be used in the compositions for use in the disclosed methods include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, di sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxy ethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, |3-, and y-cyclodextun, or chemically modified derivatives thereof, such as hydroxyalkylcyclodextrins, including hydroxypropyl-|3-cyclodextrins, such as 2- and / or 3-hydroxypropyl-p-cyclodextrins, or other solubilized derivatives thereof can also be advantageously used as a pharmaceutically acceptable carrier in the compositions described herein, e g. to enhance delivery of agents described herein.Attorney Docket No. 01367-0015-00PCT

[0129] Some embodiments of the disclosed methods comprise administering to a subject in need thereof a composition comprising a compound of the disclosure and a cyclodextrin or chemically modified derivative thereof. In some aspects, the cyclodextrin or chemically modified derivative thereof comprises a hydroxyalkylcyclodextrin, e.g, a hydroxypropyl-P- cyciodextrin. In some aspects, the compound of the disclosure and the cyclodextrin (e.g., hydroxyalkylcyclodextrin, such as hydroxypropyl-β-cyclodextrin) are present in a ratio of from about 1 to about 50 weight / weight (w / w) to about 1 to about 250 w / w, e.g, from about 1 to about 50 w / w to about 1 to about 100 w / w, about 1 to about 80 w / w or about 1 to about 166 w / w. In some aspects, the composition further comprises a diluent, such as water. In some aspects, the composition further comprises a sweetening agent and / or flavoring agent.

[0130] In some aspects, the composition is a liquid dosage form; in further aspects, the composition is a liquid dosage form for oral administration.

[0131] In some aspects, a composition for use in the disclosed methods further includes one or more additional therapeutic agents, e.g., for use in combination with a compound of the disclosure. In some embodiments, a disclosed method further comprises administering to the subject a disease modifying therapy, such as described elsewhere herein.

[0132] Some embodiments provide a combination (e.g., pharmaceutical combination) comprising a compound of the disclosure (e.g., a composition described herein comprising a compound of the disclosure) and one or more additional therapeutic agents (e.g., one or more compositions comprising one or more additional therapeutic agents, such as a disease modify ing therapy). Such combinations are particularly useful as, for example, when the compound of the disclosure and the one or more additional therapeutic agents are to be administered separately. In a combination provided herein, the compound of the disclosure and the one or more additional therapeutic agents can be admimstrable by the same route of administration or by different routes of administration.

[0133] Suitable additional therapeutic agents include those described herein with respect to combination therapies.

[0134] The compositions for use m the methods described herein can be provided in unit dosage form. The amount of active ingredient that can be combined with a carrier to produce a unit dosage form will vary' depending, for example, upon the subject being administered the composition and the particular mode of administration. Typically, a unit dosage form will contain from about 1 to about 1,000 mg of active ingredient(s), e.g., from about 1 to about 500 mg, from about 1 to about 250 mg, from about 1 to about 150 mg, from about 0.5 toAttorney Docket No. 01367-0015-00PCTabout 100 mg, or from about 1 to about 50 mg of active ingredient(s). In some aspects, a unit dosage form contains from about 0.01 mg to about 100 mg of active ingredient(s), e.g. from about 0.1 mg to about 50 mg, from about 0.1 mg to about 10 mg, from about 0.5 mg to about 50 mg of active ingredient(s). In some aspects, a unit dosage form contains from about 1 mg to about 5,000 mg of active ingredient(s) e.g., from about 10 mg to about 2,500 mg, from about 15 mg to about 1,000 mg or from about 100 mg to about 1,000 mg of active mgredient(s) In some aspects, a unit dosage form contains about 15 mg, about 30 mg, about 50 mg, about 100 mg, about 125 mg or about 150 mg of active ingredient(s).

[0135] In some aspects, the concentration of one or more therapeutic agents provided in a pharmaceutical composition is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%. 18%. 17%. 16%. 15%.14%, 13%, 12%, 11%, 10%, 9%. 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%. 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w / w, w / v or v / v; and / or greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25% 19%, 18.75%, 18.50%. 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14 50%, 14.25% 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%. 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%. 8.25% 8%. 7.75%. 7.50%. 7.25% 7%. 6.75%. 6.50%, 6.25% 6%. 5.75%, 5.50%, 5 25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%. 1.50%, 1.25%, 1%, 0.5%, 04%, 0.3%, 0.2%, 0.1%. 0.09%. 0.08%, 0.07%, 0.06%, 0.05%, 0.04?% 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%. 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w / w, w / v, or v / v

[0136] In some aspects, the concentration of one or more therapeutic agents provided in a pharmaceutical composition is in the range from about 0.0001% to about 50%, about 0.001% to about 40 %, about 0.01% to about 30%. about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%,, about 0.05% to about 26%, about 0.06% to about 25%,. about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%,, about 0.4% to about 18%, about 0.5% to about 17%, about 0,6?4> to about 16%, about 0.7% to about 15%. about 0.8% to about 14%, about 0.9% to about 12%. about 1% to about 10% w / w, w / v or v / v. In some embodiments, the concentration of one or more therapeutic agents provided in aAttorney Docket No. 01367-0015-00PCTpharmaceutical composition is in the range from about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1 %, about 0.1% to about 0.9% w / w, w / v or v / v.Numerated Embodiments

[0137] The present disclosure is further described by the following numerated embodiments. The features of each embodiment are combinable with any other embodiment or embodiments, where appropriate and practical.[00138| Embodiment Pl. A method of treating a T helper 2 (Th2) cell-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the following structural formula:or a pharmaceutically acceptable salt of the foregoing, wherein:Ring A is phenyl or (C5-C6)heteroaryl;L is ”(CH2)n", -C(O)- or -C(OH)2-;R1is H or (C1-C5)alkyl;each R2is independently chloro or fluoro;R3is (C1-C3)alkyl substituted with one or more independently selected (C6-C15)aryl or (C5-C15)heteroaryl, wherein the (C6-C15)aryl and (C5-C15)heteroaryl are each independently substituted with -each R30is independently halo, (C1-C5)alkoxy, (C1-C5)haloalkoxy, (C1-C5)alkyl or (C1-C5)haloalkyl, or two R30attached to adjacent ring atoms, taken together, form -(CH2)q- or -O(CH2)rO-;n is 1, 2 or 3;m is 0, 1. 2, 3 or 4;each p is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;each q is independently 3, 4, 5 or 6; andeach r is independently 1, 2, 3 or 4.

[0139] Embodiment P2. The method of embodiment P1, wherein Ring A is phenyl or pyridinyl

[0140] Embodiment P3 The method of embodiment Pl or P2, wherein Ring A is phenyl.Attorney Docket No. 01367-0015-00PCT

[0141] Embodiment P4. The method of any one of embodiments P1-P3, wherein L is -(CH2)n-.

[0142] Embodiment P5 The method of any one of embodiments Pl -P4, wherein R1is H.

[0143] Embodiment P6. The method of any one of embodiments Pl -P5, wherein R3is methyl substituted with one, two or three independently selected (C6-C15)aryl or (C5-C15)heteroaryl, each independently substituted with -(R30)p.

[0144] Embodiment P7. The method of any one of embodiments P1-P6, wherein R3is methyl substituted with one, two or three independently selected (C6-C15)aryl or (C5-C15)heteroaryl independently selected from phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl or benzo[d]imidazolyl, each independently substituted with -(R30)p.

[0145] Embodiment P8. Hie method of any one of embodiments P 1-P7, w herein R3is methyl substituted with one or two independently selected (C6-C15)aryl or (C5-C15)heteroaryl independently selected from phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl or benzo[d]imidazolyl, each independently substituted with -(R30)p.

[0146] Embodiment P9. The method of any one of embodiments P1-P8, wherein n is 1.

[0147] Embodiment PIO. The method of any one of embodiments P1-P9, wherein m is 0.

[0148] Embodiment P 11 The method of any one of embodiments P 1 -P 10, wherein each p is independently 0, 1 or 2.

[0149] Embodiment Pl 2. The method of embodiment P l 1, wherein each p is 0.

[0150] Embodiment P13. The method of any one of embodiments P1-P12, wherein each q is independently 3 or 4.

[0151] Embodiment P14. The method of any one of embodiments P1-P13, wherein each r is independently 1 or 2.

[0152] Embodiment P15. The method of any one of embodiments P1-P3 and P5-P14, wherein the compound comprises the following structural formula:or a pharmaceutically acceptable salt thereof, wherein:X1, X2and X3are each > C(H);X1is N, and X2and X3are each > C(H);X1and X2are each > C(H). and X3is N; orX1and X3are each >C(H), and X2is N.Attorney Docket No. 01367-0015-00PCT

[0153] Embodiment Pl 6. The method of embodiment Pl 5, wherein X1. X2and X3are each > C(H).

[0154] Embodiment P17 The method of embodiment P15, wherein X1is N, and X2and X3are each > C(H).

[0155] Embodiment PIS. The method of any one of embodiments P1-P17, wherein the -OR3is attached to the ring atom of Ring A which is meta or para to L or -(CH2)n-.

[0156] Embodiment P 19. The method of embodiment P 1, wherein the compound comprises the following structural formula:, pharmaceutically acceptable salt thereof

[0157] Embodiment P20. The method of embodiment Pl, wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0158] Embodiment P21. The method of embodiment Pl. wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0159] Embodiment P22. The method of embodiment Pl, wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0160] Embodiment P23. The method of embodiment Pl, wherein the compound comprises the following structural formula:Attorney Docket No. 01367-0015-00PCTpharmaceutically acceptable salt thereof.

[0161] Embodiment P24. The method of embodiment Pl, wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0162] Embodiment P25. The method of embodiment P 1, wherein the compound comprises the following structural formula:, or a pharmaceutically acceptable salt thereof.

[0163] Embodiment P26. 1'he method of embodiment Pl. wherein the compound comprises the following structural formula:, pharmaceutically acceptable salt thereof.

[0164] Embodiment P27 The method of embodiment Pl. wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0165] Embodiment P28. The method of embodiment Pl, wherein the compound comprises the following structural formula:pharmaceutically acceptable salt thereof.

[0166] Embodiment P29. The method of any one of embodiments P1-P28, wherein the compound, or pharmaceutically acceptable salt thereof, is administered orally.Attorney Docket No. 01367-0015-00PCT

[0167] Embodiment P30. I’he method of any one of embodiments P1-P29, wherein the compound, or pharmaceutically acceptable salt thereof, is administered to the subject in need thereof once per day, twice per day, more than twice per day, once every two days, once every three days, once every four days, once even' five days, once every six days, once every seven days, or less than once even' seven days.

[0168] Embodiment P31. The method of any one of embodiments P1-P30, wherein the compound, or pharmaceutically acceptable salt thereof, is administered to the subject in need thereof once daily.

[0169] Embodiment P32. The method of any one of embodiments P1-P31, further comprising administering to the subject a disease-modifying therapy.

[0170] Embodiment P33. The method of any one of embodiments Pl -P32, wherein the subject was previously treated with a disease-modifying therapy.

[0171] Embodiment P34. The method of any one of embodiments P1-P33, wherein prior to the treatment with the compound, or pharmaceutically acceptable salt thereof, the subject had an inadequate response to and or experienced a grade 2 or greater adverse event related to a systemic or topical disease-modifying therapy for the Th2 cell-mediated disorder.

[0172] Embodiment P35 The method of embodiment P34, wherein the inadequate response and / or the grade 2 or greater adverse event comprises skin atrophy, an allergic reaction, or a systemic effect that outweighed the benefits of the therapy.

[0173] Embodiment P36. The method of any one of embodiments P32-P35, wherein the disease-modifying therapy comprises a topical corticosteroid, a topical immune modulator, a topical phosphodiesterase type 4 (PDE 4) inhibitor, a topical JAK inhibitors, a topical aryl hydrocarbon receptor agonist, a topical or systemic antihistamine, an emollient, an oral systemic immunosuppressive and / or immunomodulating therapy, a cell depleting therapy, dupilumab, tralokmumab, ustekinumab, secukinumab, ixikizumab, an anti-TNF inhibitor, PUVA phototherapy, or UVB phototherapy.

[0174] Embodiment P37. The method of any one of embodiments P1-P36, wherein the subject is a mammal.

[0175] Embodiment P38. The method of any one of embodiments P1-P37, w'herem the subject is a human

[0176] Embodiment P39. The method of any one of embodiments P1-P38, wherein the Th2-mediated disorder is atopic dermatitis (eczema), allergic asthma, graft versus host disease, progressive systemic sclerosis (scleroderma), rhinosinusitis, prurigo nodularis, anAttorney Docket No. 01367-0015-00PCTeosinophilic gastrointestinal disorder, a systemic allergic reaction, a hypereosinophilic syndrome, or a food allergy.

[0177] Embodiment P40 The method of any one of embodiments P1-P39, wherein the Th2-mediated disorder is atopic dermatitis (eczema).

[0178] Embodiment P41. The method of embodiment P40, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an eczema area and severity index (EASI) score of Jess than or equal to 50, less than or equal to 40, less than or equal to 30, less than or equal to 25, less than or equal to 20, less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16, less than or equal to 15, less than or equal to 14, less than or equal to 13, less than or equal to 12, less than or equal to 11, or less than or equal to 10, less than or equal to 5, or zero.

[0179] Embodiment P42. The method of embodiment P41, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an eczema area and severity index (EASI) score of less than or equal to 16.

[0180] Embodiment P43. The method of any one of embodiments P40-P42, wherein prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score of greater than or equal to 16.

[0181] Embodiment P44. The method of any one of embodiments P40-P43, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an EASI score that is at least 20 percent lower than an EASI score of the subject at day 0 of the treatment period.

[0182] Embodiment P45. The method of any one of embodiments P40-P44, wfierem following 28 days of treatment with the compound, or the pharmaceutically' acceptable salt thereof, the subject has a validated investigator’s global assessment scale (vIGA) score of less than or equal to 2, less than or equal to 1, or 0

[0183] Embodiment P46 The method of any one of embodiments P40-P45, wherein prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a vIGA score of greater than or equal to 3.

[0184] Embodiment P47. 1’he method of any one of embodiments P40-P46, w'herein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a vIGA score that is at least 20 percent lower than a vIGA score of the subject at day' 0 of the treatment period.

[0185] Embodiment P48. The method of any one of embodiments P40-P47, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable saltAttorney Docket No. 01367-0015-00PCTthereof, the subject has a pruritic numerical rating scale (NRS) score of less than or equal to 6, less than or equal to 5, less than or equal to 4. less than or equal to 3. less than or equal to 2, less than or equal to 1, or zero.

[0186] Embodiment P49. The method of any one of embodiments P40-P48, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a pruritic numerical rating scale (NRS) score of less than or equal to 4

[0187] Embodiment P50. The method of any one of embodiments P40-P49, wherein prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an NRS score of greater than or equal to 4.

[0188] Embodiment P51. The method of any one of embodiments P40-P50, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has an NRS score that is at least 20 percent lower than an NRS score of the subject at day 0 of the treatment period.

[0189] Embodiment P52. The method of any one of embodiments P40-P51, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent body surface area (BSA) involvement of less than or equal to 50%, less than or equal to 40%, less than or equal to 30%, less than or equal to 20%, less than or equal to 15%, less than or equal to 14%, less than or equal to 13%, less than or equal to 12%, less than or equal to 11%. less than or equal to 10%, less than or equal to 9%, less than or equal to 8%, less than or equal to 7%, less than or equal to 6%, less than or equal to 5%, less than or equal to 4%, less than or equal to 3%, less than or equal to 2%, or less than or equal to 1 %.

[0190] Embodiment P53. The method of any one of embodiments P40-P52, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent body surface area (BSA) involvement of less than or equal to 10%.

[0191] Embodiment P54. The method of any one of embodiments P40-P53, wherein prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent BSA of greater than or equal to 10%.

[0192] Embodiment P55. The method of any one of embodiments P40-P54, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject has a percent BSA that is at least 20 percent lower than a percent BSA of the subject at day 0 of the treatment period.Attorney Docket No. 01367-0015-00PCT

[0193] Embodiment P56. A compound having the following structural formula:or a pharmaceutically acceptable salt of the foregoing, wherein:Ring A is phenyl or (C5-C6)heteroaryl;L is -(CH2)n-, -C(O)- or -C(OH)2-;R1is H or (C1-C5)alkyl;each R2is independently chloro or fluoro;R3is (C1-C3)alkyl substituted with one or more independently selected (C6-C15)aryl or (C5-C15)heteroaryl, wherein the (C6-C15)aryl and (C5-C15)heteroaryl are each independently substituted with -(R30)p;each R30is independently halo, (C1-C5)alkoxy, (C1-C5)haloalkoxy, (C1-C5)alkyl or (C1-C5)haloalkyl, or two R30attached to adjacent ring atoms, taken together, form -(CH2)q- or -O(CH2)rO-;n is 1, 2 or 3;m is 0, 1, 2, 3 or 4;each p is independently 0, 1, 2, 3, 4, 5, 6, 7, 8. 9 or 10;each q is independently 3, 4. 5 or 6; andeach r is independently 1, 2, 3 or 4;for use in treating a T helper 2 (Th2) cell-mediated disorder.EXEMPLIFICATIONExample 1. Ex vivo Evaluation of Compound 2 Pharmacology in Allergic Asthma (a Th2-Derived Disorder)

[0194] This Example describes an ex vivo study wherein PBMCs from subjects with allergic asthma were incubated with Compound 2. Results showed a significant increase in the percentage of regulatory T cells (Tregs) and a significant decrease in Th2 cells after five days of culture with Compound 2.Materials and Methods

[0195] Materials and reagents used in this Example are provided in Table 2.Table 2.Attorney Docket No. 01367-0015-00PCTClinical Sample Collection Allergic Asthma Patient PBMCs

[0196] Cryopreserved PBMCs from six patients diagnosed with allergic asthma were obtained from Sanguine. Each patient sample contained 10 x 106cells.Clinical Sample Collection - Patient Records

[0197] Patient records and medical history are summarized in Table 3.Table 3. Allergic asthma patient recordsAttorney Docket No. 01367-0015-00PCTPreparation of Compound 2

[0198] A stock solution of 1 mg / ml of Compound 2 was prepared by dissolving 0.5 mg of Compound 2 in 0.5 ml of DMSO.Treatment of PBMCs with Compound 2

[0199] PBMCs of the allergic asthma patients were suspended in complete DMEM media (containing 10% fetal bovine serum. 1% penicillin / streptomycin, 1% L-glutamine, and 0.1% 2-mercaptoethanol), and cell concentration was adjusted for 2 x 106cells / ml, 100 pl of total PBMCs were plated in wells of a 96-well round bottom plate. The wells were dosed with 100 pl of Compound 2. The following concentrations were tested: 0, 0.1, 0.3, 1. 3, 5, and 10 ng / ml. Cells were incubated at 37 °C for five days. At the end of the incubation period, cells were washed and prepared for flow cytometry analysis.Cell Staining and Flow Cytometry Analysis

[0200] Cells recovered from allergic asthma patients at day 0 (baseline), and cells after five days of treatment as described above were stained as follows. Ninety -six-well plates were spun down and washed with FACS buffer. Samples were then incubated with 25 pl of FcBlock (1:100 in FACS buffer) for 15 minutes on ice. Following this, 50 pl of FACS buffer containing 1 pl each of anti-CD3 and anti-CD4 antibodies were added to the samples and incubated for 30 minutes on ice. After incubation, samples were washed once with FACS buffer and twice with protein-free PBS, spinning down the samples at 600g for 2 minutes at 4 °C after each wash. Samples were then incubated with 50 pl of Fixable viability dye (1: 1000 in PBS) for 1 minutes on ice. Samples were then w ashed with PBS three times, spinning down at 600g for 2 minutes at 4 °C after each wash. Cells were then fixed in Fix / Prem buffer for a minimum of 30 minutes and up to overnight at 4 °C. After fixation, cells w ere spun down at 600g for 2 minutes and washed once with perm buffer, again spinning down at 600g for 2 minutes at 4 °C after each wash. Subsequently, cells were fixed for 30 minutes with Fix / Perm buffer. Cells w-ere then incubated with 25 pl of perm buffer containing 1:100 FcBlock for 15 minutes, follow ed by the addition of 50 pl of perm buffer containing 2 pl of Foxp3 and Gata 3 antibodies, and incubated for 30 minutes on ice. Cells w ere then washed twice with perm buffer and once with FACS buffer, spinning down at 600g for 2 minutes at 4 °C after each w7ash. Finally, cells w7ere fixed for flow cytometry acquisition.Attorney Docket No. 01367-0015-00PCTResultsT-reg and Th2 Phenotype in Patients with Allergic Asthma

[0201] Flow cytometer analysis showed a higher percentage of Th2 cells (as characterized by Gata3 expression) than Tregs (as characterized by Foxp3 expression) in samples from patients with allergic asthma (FIG. 1).

[0202] In Vitro Effect of Compound 2 on T-cells from Patients with Allergic Asthma After Five Days of Culture

[0203] Analysis of CD4+T cells at the end of five days of culture in the presence of Compound 2 showed a dose-dependent increase in CD4+ / Foxp3+ Tregs and a dose¬ dependent decrease in Th2 cells (as characterized by Gata3 expression) in PBMCs from allergic asthma patients (n=6) (FIG. 2).Discussion

[0204] This study showed that patients with allergic disease exhibit increased Th2 cells and decreased Treg cells. Treatment of allergic asthma patient-derived PBMCs with Compound 2 reduced expression of Gata3, a marker of Th2 cells, while simultaneously increasing the percentage of Treg cells in a dose-dependent manner. These results suggest a potential clinical application for Compound 2 in Th2-driven diseases, such as allergic asthma and atopic dermatitis.Example 2. A Phase IB Randomized, Double-Blind, Placebo-Controlled Study in Participants with Atopic Dermatitis (AD) to Evaluate Safety, Tolerability and Pharmacokinetics of Compound 2

[0205] This Example describes a Phase lb, multi-center, randomized, double-blind, placebo-controlled multiple dose study in participants with moderate to severe atopic dermatitis. Compound 2 will be administered as an oral solution for 28 days. The primary objective of this study is to evaluate the safety and tolerability after multiple oral doses of Compound 2 m participants with atopic dermatitis. Secondarily, the study will evaluate plasma pharmacokinetics after multiple oral doses of Compound 2 m the participants.

[0206] The AD study cohort will consist of, e.g., approximately 20-to-24 parti cipants. Based on available safety, pharmacodynamics (PD), and pharmacokinetics (PK), a recommended dose will be selected and subjects will be randomized (3: 1 Compound 2 treatmentplacebo) at the recommended dose for 28 days.

[0207] Participants will be observed after dosing through completion of all scheduled procedures. The study drug will be administered orally as a solution and a single dose per day in the fasted state. The participants will receive the oral solution at site on Days 1, 2, 7, 14.Attorney Docket No. 01367-0015-00PCT21, 28. For the remaining days, the participants will receive oral solutions in dispensable bottles labeled for each day for up to 7 following days and will self-admimster at home.

[0208] The total duration of the study will be 56 days, including once daily dosing on an empty stomach in the morning at least one hour before breakfast for 28 days, and a 28-day follow-up period after the last dose. Participants will be confined in the clinic or close to the clinic during visit 1 for 2 nights and visit 5 for 2 nights.

[0209] The study will evaluate treatment efficacy for atopic dermatitis using eczema area and severity index (EASI), validated investigator's global assessment scale (vIGA). body surface area (BSA) involvement, and pruritis numerical rating scale (NRS).MethodsEligibility Criteria - Inclusion Criteria1. Subject has signed an Informed Consent Form (ICF) pnor to any study-specific procedures being performed.2. Subject is greater than or equal to 18 years old, irrespective of race and ethnicity.3. Body Mass Index (BMI) 18.0-40.0 kg / m2, inclusive, at screening.4. Participants are willing and able to adhere to study protocol requirements and restrictions including but not limited to scheduled outpatient visits, inpatient stay, laboratory' tests, and 12-lead electrocardiograms (ECGs).5. The subject must be judged to be m good health by the investigator to participate in the study, based on clinical evaluations, including laboratory' safety tests, medical history, physical examination, vital signs and 12-lead ECG completed at the screening visit and prior to the first dose of study drug.6. Female subject is postmenopausal (at least I year; to be confirmed by follicle stimulating hormone (FSH) if less than 2 years since last menstrual period), permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or if of childbearing potential and engaged in sexual activity thatcan result in pregnancy must agree to use any two of the highly effective contraception methods listed below. Male participants with a partner of childbearing potential must also agree to use any two of the highly effective contraception methods listed below between them and their partner. This criterion must be followed from screening visit to 6 weeks after the last dose in females and for 90 days after the last dose for males The following applies to all female participants with childbearing potential and female partners of male participants enrolled in the study.a) Implantable progestogen-only hormone contraception associated with inhibition of ovulation.Attorney Docket No. 01367-0015-00PCTb) Intrauterine device.c) Intrauterine hormone-releasing system.d) Bilateral tubal occlusion.e) Combined (estrogen- and progestogen-containing) hormonal contraception f) associated with inhibition of ovulation:g) Oralh) Intravaginali) Transdermalj) Injectablek) Progestogen-only hormone contraception (oral or injectable) associated with inhibition of ovulation.l) V asectomized partnerin) Sexual abstinence - this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated about the duration of the study and the preferred and usual lifestyle of the participant.n) A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods)The following applies to all male participants in the study:o) Sexual abstinence - this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence must be evaluated for the study and the participant's preferred and usual lifestyle.p) A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).q) Vasectomy7. Negative serum B-human chorionic gonadotropin test at screening (for all females) and negative urine pregnancy at randomization (Day 1) (females of childbearing potential) prior to administration of investigational product.8. Diagnosis of AD at least 12 months prior to screening, as defined by the American Academy of Dermatology: Guidelines of care for the management of atopic dermatitis (Eichenfield et al. 2014)Attorney Docket No. 01367-0015-00PCTr) EASI score > 16 at Screening and baseline (Day 0).s) vIGA score of >3 at screening and baseline (Day 0).t) >10% of body surface area (BSA) involvement at screening and baseline (Day 0).u) Peak pruntis NRS>4 (average score of daily scores 7 days before Day 0) 9. History, documented by a physician and / or investigator, of inadequate response to existing topical medications within 6 months preceding screening, or hi st on / of intolerance to topical therapy as defined by at least 1 of the following:a) Inability to achieve good disease control defined as mild disease or better (e.g., vIGA<2) after use of at least a medium potency topical corticosteroid (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (e.g. 14 days for super potent TCS), whichever is shorter (Note: a TCS may be used with or without topical calcmeurin inhibitors [TCNlsj) b) Documented hi story of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or sy stemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment c) Failed systemic therapies intended to treat AD within 6 months preceding screening (will be considered as having inadequate response to topical therapy) 10. Documented history of clinically significant adverse reactions with the use of TCS, such as skm atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment.11. Failed systemic therapies intended to treat AD within 6 months preceding screening (will be considered as having inadequate response to topical therapy).Eligibility Criteria - Exclusion Criteria1 History’ of clinically' significant medical conditions or any other reason that in the opinion of the principal investigator (PI) would interfere with a subject’s participation in this study.2. History of clinically significant drug or alcohol abuse per the Pi's opinion within the last 6 months.3. Pregnant or lactating women or women currently undergoing infertility' treatments or women who intend to become pregnant during the time of study or for 6 w'eeks after last dose.4 Presence of skin comorbidities that would interfere with study assessment or response to treatment.Attorney Docket No. 01367-0015-00PCT5. Any known history' of malignancy within 5 years other than completely treated non- metastatic basal cell carcinomas or squamous cell carcinomas of the skin or localized carcinoma in situ of the cervix.6. Patients who are currently experiencing a skin infection that requires treatment, oris currently being treated, with topical or systemic antibiotics.7. Symptomatic herpes zoster within 3 months of screening.8 Receipt of an investigational therapy less than 3 months or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study. 9. Use of the following topical medications / emollients which could affect assessment of disease activity for at least 2 weeks prior to baseline (Day 0) and throughout the study:a) Topical corticosteroids or topical immune modulators (e.g. tacrolimus or pimecrolimus).b) Topical phosphodiesterase type 4 (PDE 4) inhibitor or JAK inhibitors or aryl hydrocarbon receptor agonists.c) Topical or systemic antihistaminesd) Use of emollients.10. Receipt of any of the following excluded therapies as per below' and throughout the study:a) Oral retinoids within 2 weeks of Day 0.b) Systemic immunosuppressive / immunomodulating therapy (such as but not limited to systemic glucocorticoids, cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, apremilast, or oral JAK inhibiting agents or phototherapy within 4 weeks before screening visit. Stable dose of max 1200ug inhaled budesonide (or equivalent) is allowed.c) Any cell depleting therapy. anti-CD4, anti-CD5, anti-CD3 other than anti- CD20 such as rituximab, ocrelizumab, and ofatumumab Patients wito have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to screening.11. Biologies drugs including, but not limited to, dupilumab, tralokinumab, ustekinumab, secukinumab. ixikizumab, anti-TNF inhibitors within 8 weeks or 5 drug elimination half-lives whichever is longer and throughout the study.12. Failed biologics due to efficttcy including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab. anti-TNF inhibitors.13. PUVA or UVB phototherapy within 4 weeks prior to Day 0 and throughout the study.Attorney Docket No. 01367-0015-00PCT14. Subject has clinical or laboratory evidence of active or latent tuberculosis (TB) infection at screening as assessed by QuantiFERON-TB-Gold or a purified protein derivative skin test or equivalent (or both if required per local guidelines) and chest X-ray. Chest X-rays taken within 2 months prior to screening may be used instead of during screening if there is documentation showing no evidence of infection or malignancy as read by qualified physician.15, Any active or recurrent infection within 1) the past 8 weeks prior to screening requiring IV / hospitalization or 2) the past 2 weeks prior to screening requiring oral antibiotics 6. Laboratory' values of the following at the Screening Visit:a) Hemoglobin < 11 g / dL.b) White blood cells (WBCs) <3.5X109 / 1..c) Absolute neutrophil count (ANC) < 1500 cells / pL, (or < 1200 cells / pL for participants of African descent who are Black).d) Aspartate aminotransferase or alanine aminotransferase > 2.0 x the upper limit of normal (ULN) or bilirubin >= ULN.e) Bilirubin > ULN.f) Platelets < 100,000 cells / [mmA3] (10A9 / L).g) Clinically significant abnormal screening laboratory results as evaluated by the Investigator.17. Acutely’ worsened renal function within the past 3 months prior to screening or estimated glomerular filtration rate (GFR) by CKD-EPI creatinine equation with adjustment for body surface area < 60ml / min.18. Subject has any clinically significant finding on 12-lead ECG at screening or admission. NOTE: QTc(F) interval of >450 msec in male participants or >470 msec in female participants will be the basis for exclusion from the study. ECG may be repeated once for confirmatory' purposes if initial values obtained exceed the limits specified19. Subject with positive results for HBsAg (hepatitis B surface antigens) and / or HBcAb (Hepatitis B core antibodies) and / or HCV Ab (hepatitis C antibodies) confirmed by HCV RNA, and / or HIV Ab (human immunodeficiency virus antibodies).20. Blood loss of >250 mL or donated blood within 56 days or donated plasma within 7 days of screening.21. Recent vaccination with live attenuated vaccines such as influenza, MMR, Herpes zoster, varicella, yellow fever. Rotavirus vaccine, etc., or inactivated vaccines such as Hepatitis A, rabies vaccine, etc. 30 days prior to screening visit.Attorney Docket No. 01367-0015-00PCT22. Subject has known sensitivity to any of the components of the investigational product. 23. Subject is investigative site personnel, sponsor personnel, or a member of their immediate families (spouse, parent, child or sibling whether biological or legally adopted).Duration of Treatment

[0210] The participants are given QD dosing for 28 days and then followed up for 28 days.Criteria for Evaluation

[0211] Safety>: Frequency and severity- of all adverse events / serious adverse events (AEs / SAEs) after multiple oral doses of Compound 2.

[0212] Pharmacokinetics: Measuring the PK parameters such as area under the plasma concentration-time curve (AUC), maximum observed plasma concentration (Cmax), Time to first occurrence of Cmax(Tmax). etc. after single dose administration of Compound 2, and AUC steady-state, Cave,steady-state, Ctrough,steady-state, and accumulation ratio of Compound 2 after multiple oral doses of Compound 2.

[0213] Efficacy Assessments: The study will evaluate treatment efficacy for atopic dermatitis using eczema area and seventy index (EASI), validated investigator’s global assessment scale (A IGA), body surface area (BSA) involvement, and pruritis numerical rating scale (NRS).

[0214] Photographs will be taken of a representative area of atopic dermatitis (e.g. lesioned area used for EASI assessments) involvement on day 0 (predose). Subsequent photographs of the same area will be taken at day 28 (end of treatment), and day 56 (end of study). The same camera, magnification and settings for each photograph should be used at each visit to evaluate changes over time. Photographs should be labelled with study number, subject number, visit name and date.Check in and Treatment Period

[0215] Visit 1 (VI) will involve confinement at the clinical site from Day 0 to Day 2 Procedures to be completed at Check-in (Day 0) include the following: Inclusion / exclusion criteria assessments including confirmation that participant meets disease specific inclusion criteria; concomitant medications: weight, height, and BMI; physical examination: alcohol and drug screening; vital signs; clinical laboratory tests; urine pregnancy test (if females of child-bearing potential); QuantiFeron TB Gold test (and local purified protein derivative (PPD) skin test if required); efficacy assessments; urine analysis; ECG recording; and adverse effects (AE) reporting.Attorney Docket No. 01367-0015-00PCT

[0216] Procedures to be completed on Day 1 include the following: vital signs; clinical laboratory tests; study drug administration; pharmacokinetic sampling (Blood Sample Collection); pharmacodynamic sampling (Plasma and Whole Blood Sample Collection); ECG recording; and AE Reporting

[0217] Procedures to be completed on Day 2 include the following: vital signs; clinical laboratory tests; study drug administration; study drug dispensing; pharmacokinetic sampling (Blood Sample Collection); and AE Reporting,

[0218] Visit 5 (V5) will involve confinement at the clinical site from Day 27 to Day 29. Procedures to be completed at Check-in (Day 27) include the following: concomitant medications; vital signs; clinical laboratory tests; alcohol and drug screening: study drug administration; pharmacokinetic sampling (Blood Sample Collection); pharmacodynamic sampling (Whole Blood Sample Collection): and AE Reporting.

[0219] Procedures to be completed on Day 28 include the following: vital signs; clinical laboratory tests; study drug administration; pharmacokinetic sampling (Blood Sample Collection); pharmacodynamic sampling (Plasma and Whole Blood Sample Collection); and AE Reporting

[0220] Procedures to be completed on Day 29 include the following: vital signs; physical examination; clinical laboratory tests; urine analysis; urine pregnancy test; efficacy assessments; pharmacokinetic sampling (Blood Sample Collection); pharmacodynamic sampling (Whole Blood Sample Collection); ECG recording; and AE reporting.

[0221] Outpatient visits will occur on the following days: Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21), Visit 6 (Day 35), and Visit 7 (Day 42). Procedures to be completed during V2 include the following: medical and surgical history and concomitant medication history; weight, height, and BMI (only on Days 14 / 35 / 42); vital signs; clinical laboratory tests; rheumatoid factor and anti-CCP antibodies (only on Days 14 / 42); urine analysis (only on Day 14); alcohol and drug screening (only on Days 7 / 35); pharmacodynamic assessments (Whole Blood Sample Collection); ECG recording (only on Days 14 / 35 / 42); efficacy assessments (including check for completion of daily pruritis scale; and AE Reporting.

[0222] The end of study visit (Visit 8) will occur on Day 56. Procedures to be completed during V8 include the following: medical and surgical history and concomitant medication history; physical examination; weight, height, and BMI; vital signs; clinical laboratory tests; pregnancy test (if female of child-bearing potential); urine analysis; pharmacodynamic assessments (Whole Blood Sample Collection); efficacy assessments; ECG recording; and AE Reporting.Attorney Docket No. 01367-0015-00PCTExample 3. A Phase IB Randomized, Double-Blind, Placebo-Controlled Study in Participants with Atopic Dermatitis (AD) to Evaluate Safety, Tolerability and Pharmacokinetics of Compound 2

[0223] This study was carried out in accordance with the general protocol described in Example 2 with the following differences:Study Design

[0224] The AD study cohort w ill consist of approximately 20-to-24 participants (total up to 48 participants in the trial) treated QD for 28 days. The participants will receive either 150 mg, 300 mg, 450 mg, or 600 mg Compound 2 QD in a solid oral form or placebo QD for 28 days (3: 1 active:placebo randomization). The first 4 to 8 participants of the AD cohort will receive 150 mg Compound 2, and the remaining participants (up to 20 participants) will be randomized to receive either 300 mg, 450 mg, or 600 mg for 28 days in 3:1 active:placebo ratio.Eligibility Criteria - Inclusion Criteria

[0225] 3. Body Mass Index (BMI) 18.0-42,5 kg / m2, inclusive, at screening

[0226] Eligibility Criteria - Inclusion Criteria described in Example 2 further include: 12. Use of a stable amount of a bland (non-medicated, urea- and lactic acid free-) emollient therapy before or from screening visit and throughout the study.Duration of Treatment

[0227] The participants are given QD dosing for 28 days and then followed up for 56 days.Check in and Treatment Period

[0228] Pharmacodynamic assessments include plasma and whole blood sample collection. Plasma samples will be collected on the following days and used for PD analyses: Visit 1 (Day 1), Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21), Visit 5 (Day 28), Visit 6 (Day 35), Visit 7 (Day 42), Visit 8 (Day 56), Visit 9 (Day 70), and Visit 10 (Day 84). Whole blood will be collected on the following days and used for PD analyses: Visit 1 (Day 1), Visit 2 (Day 7), Visit 3 (Day 14), Visit 4 (Day 21), Visit 5 (Day 29), Visit 6 (Day 35), Visit 7 (Day 42), Visit 8 (Day 56), Visit 9 (Day 70), and Visit 10 (Day 84).Results

[0229] FIGs. 3A-D show the EASI scores from four patients in the AD cohort treated with Compound 2 or placebo correlated with Th2 levels.Attorney Docket No. 01367-0015-00PCT

[0230] The teachings of all patents, published applications, and references cited herein are incorporated by reference in their entirety.

[0231] While example embodiments have been particularly show and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the embodiments encompassed by the appended claims.

Claims

Attorney Docket No. 01367-0015-00PCTCLAIMSWhat is claimed is:

1. A method of treating a T helper 2 (Th2) cell-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the following structural formula:or a pharmaceutically acceptable salt of the foregoing, wherein:Ring A is phenyl or (C5-C6)heteroaryl;L is -(CH2)n-, -C(O)- or -C(OH)2-;R1is H or (C1-C5)alkyl,each R2is independently chloro or fluoro;R3is (C1-C3)alkyl substituted with one or more independently selected (C6-C15)aryl or (C5-C15)heteroaryl, wherein the (C6-C15)aryl and (C5-C15)heteroaryl are each independently substituted with -(R30)p;each R30IS independently halo. (Ci-Cs)alkoxy. (Ci-Csjhaloalkoxy. (Ci-Csjalkyl or (Ci-Cslhaloalkyl, or two R’° attached to adjacent ring atoms, taken together, form -(CII2)q- or -O(CII2)rO-;n is 1, 2 or 3;m is 0, 1, 2, 3 or 4;each p is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;each q is independently 3, 4, 5 or 6; andeach r is independently 1, 2, 3 or 4.

2. The method of claim 1, wherein Ring A is phenyl or pyridinyl; optionally wherein Ring A is phenyl.

3. The method of claim 1 or 2, wherein L is -(CH2)n-.

4. The method of any one of claims 1 -3, wherein R1is H5. The method of any one of claims 1-4, wherein R3is methyl substituted with one, two or three independently selected (C6-C15)aryl or (C5-C15)heteroaryl, each independentlyAttorney Docket No. 01367-0015-00PCTsubstituted with -(R30)p; optionally wherein R3is methyl substituted with one, two or three independently selected (C6-C15)aryl or (C5-C15)heteroaryl independently selected from phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl, or benzo[d]imidazolyl, each independently substituted with -; or optionally wherein R3is methyl substituted with one or two independently selected (C6-C15)aryl or (C5-C15)heteroaryl independently selected from phenyl, naphthyl, pyridinyl, quinolinyl, isoquinolinyl, or benzo[d]imidazolyl, each independently substituted with -(R30)p.

6. The method of any one of claims 1-5, wherein:(i) n is 1;(ii) m is 0;(iii) each p is independently 0, 1, or 2; optionally wherein each p is 0;(iv) each q is independently 3 or 4; and / or(v) each r is independently 1 or 2.

7. The method of any one of claims 1, 2, and 4-6, wherein the compound has the following structural formula:or a pharmaceutically acceptable salt thereof, wherein:X1. X2and X3are each C(H);X1is N. and X2and X3are each C(H);X1and X2are each C(H), and X3is N; orX1and X3are each C(H), and X2is N.8 The method of claim 7, wherein (i) X1, X2, and X3are each C(H) or (ii) X1is N, and X2and X3are each C(H).

9. The method of any one of claims 1-8, wherein the -OR3is attached to the ring atom of Ring A which is meta or para to L or -(CH2)n-.

10. The method of claim 1, wherein the compound has one of the following structural formulas:Attorney Docket No. 01367-0015-00PCTor a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein the compound has the following structural formula:, or a pharmaceutically acceptable salt thereof.

12. The method of any one of claims 1-11, wherein the compound, or pharmaceutically acceptable salt thereof, is administered orally.

13. The method of any one of claims 1-12, wherein the compound, or pharmaceutically acceptable salt thereof, is administered to the subject once per day, twice per day, more than twice per day, once every two days, once every three days, once every four days, once every five days, once every' six days, once every seven days, or less thanAttorney Docket No. 01367-0015-00PCTonce every seven days; optionally wherein the compound, or pharmaceutically acceptable salt thereof, is administered to the subject once daily.

14. The method of any one of claims 1-13, further comprising administering to the subject a disease-modifying therapy; optionally wherein the subject was previously treated with a disease-modifying therapy; and optionally wherein the disease-modifying therapy comprises a topical corticosteroid, a topical immune modulator, a topical phosphodiesterase type 4 (PDE 4) inhibitor, atopical JAK inhibitors, a topical aryl hydrocarbon receptor agonist, a topical or systemic antihistamine, an emollient, an oral systemic immunosuppressive and / or immunomodulating therapy, a cell depleting therapy, dupilumab, tralokinumab. ustekinumab, secukinumab, ixikizumab, an anti- TNF inhibitor, PUVA phototherapy, or UVB phototherapy.

15. The method of any one of claims 1-14, wherein prior to the treatment with the compound, or pharmaceutically acceptable salt thereof, the subject had an inadequate response to and / or experienced a grade 2 or greater adverse event related to a systemic or topical disease-modifying therapy for the Th2 cell-mediated disorder; optionally wherein the inadequate response and / or the grade 2 or greater adverse event comprises skin atrophy, an allergic reaction, or a systemic effect that outweighed the benefits of the therapy.

16. The method of any one of claims 1-15, wherein the subject is a mammal; optionally wherein the subject is a human.

17. Tire method of any one of claims 1-16. wherein the Th2-mediated disorder is atopic dermatitis (eczema), allergic asthma, graft versus host disease, progressive systemic sclerosis (scleroderma), rhinosinusitis, prurigo nodularis, an eosinophilic gastrointestinal disorder, a systemic allergic reaction, a hypereosinophilic syndrome, or a food allergy.

18. The method of any one of claims 1-17, wherein the Th2-mediated disorder is atopic dermatitis (eczema).

19. The method of claim 18, wherein following 28 days of treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject:(i) has an eczema area and severity index (EASI) score of less than or equal to 50, lessAttorney Docket No. 01367-0015-00PCTthan or equal to 40, less than or equal to 30, less than or equal to 25, less than or equal to 20. less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16. less than or equal to 15, less than or equal to 14, less than or equal to 13, less than or equal to 12, less than or equal to 11, or less than or equal to 10, less than or equal to 5, or zero; optionally wherein the subject has an EASI score of less than or equal to 16;(ii) has an E AST score that is at least 20 percent lower than an EASI score of the subject at day 0 of the treatment period;(iii) has a validated investigator’s global assessment scale (viGA) score of less than or equal to 2, less than or equal to I, or 0;(iv) has a vIGA score that is at least 20 percent lower than a vIGA score of the subject at day 0 of the treatment period;(v) has a pruritic numerical rating scale (NRS) score of less than or equal to 6, less than or equal to 5, less than or equal to 4, less than or equal to 3, less than or equal to 2. less than or equal to 1. or zero; optionally wherein the subject has an NRS score of less than or equal to 4;(vi) has an NRS score that is at least 20 percent lower than an NRS score of the subject at day 0 of the treatment period;(vii) has a percent body surface area (BSA) involvement of less than or equal to 50%, less than or equal to 40?% less than or equal to 30%. less than or equal to 20%, less than or equal to 15%, less than or equal to 14%, less than or equal to 13%, less than or equal to 12?% less than or equal to 11 %, less than or equal to 10%, less than or equal to 9%, less than or equal to 8%, less than or equal to 7%, less than or equal to 6%, less than or equal to 5%, less than or equal to 4%, less than or equal to 3?% less than or equal to 2%. or less than or equal to 1%; optionally wherein the subject has a percent BSA involvement of less than or equal to 10%; and / or(viii) has a percent BSA that is at least 20 percent lower than a percent BSA of the subject at day 0 of the treatment period.

20. The method of claim 18 or 19, wherein prior to treatment with the compound, or the pharmaceutically acceptable salt thereof, the subject:(i) has an EASI score of greater than or equal to 16;(ii ) has a viGA score of greater than or equal to 3;Attorney Docket No. 01367-0015-00PCT(iii) has an NRS score of greater than or equal to 4; and / or(iv) has a percent BSA of greater than or equal to 10%.